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On behalf of the College of Veterinary Medicine, I would like to extend a warm 
welcome to you. The 2014 Minnesota Dairy Health Conference is part of the 
college’s commitment to offering current research in practical contexts to both 
practitioners and producers.  Your partnership in this educational process with us 
ensures improved management, healthy herds and a safer food supply.  
 
Over the past year the private-public partnership at the Dairy Education Center has 
continued to flourish and we are very pleased to have this wonderful collaboration. In addition, I 
would like to highlight that Dr. Erin Royster joined our dairy team earlier this year. She will be 
working closely with the VDL’s Udder Health Laboratory and will be providing her expertise in the 
assessment of parlor systems. The research of the members of our dairy group is also continuing to 
grow in the areas of lameness, reproduction, calf health, udder health, organic dairying and 
stockmanship.  
 
We are thrilled to offer you a fabulous program covering an array of the latest applied research 
which features leading dairy industry speakers from across the United States and Canada.  Joining 
this roster of presenters is a group I am especially proud to call my colleagues.  Our dairy faculty and 
graduate students here at the University of Minnesota will further enrich the program by presenting 
their most current research.   
 
In addition, I want to thank the sponsors and exhibitors of this annual conference. Your support 
makes this educational exchange possible.  We especially appreciate the interest you take in our 
students’ research, education and careers. I am fortunate to see the high level of quality in students 
entering the field of food animal veterinary medicine today and your mentorship and support of 
these students is critical to the industry. 
 
And finally, a special thank you to Dr. Riki Sorge for her committee’s steadfast and visionary 
leadership of this conference.  The conference’s scientific program remains vibrant and timely due to 
the attention and involvement of our entire dairy faculty here at the University of Minnesota’s 
College of Veterinary Medicine. 
 
Thank you for joining us.  
Sincerely, 
 
Trevor R. Ames, D.V.M., M.S., Diplomate ACVIM 
Dean, College of Veterinary Medicine 
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Economics of Culling 
John Fetrow1 VMD, MBA Professor of Dairy Production Medicine & Steve Eicker2 DVM, MS 
1 College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108 
2 Valley Ag Software, King Ferry, NY 13081 
 
 
 
 
 Culling is an inevitable event in every dairy cow’s life (in this context culling includes 
death on the dairy).  Industry-wide herd turnover rates (percent of the adult inventory on a dairy 
that leaves within a year) certainly varies between farms. The differences between farms are due 
to a complex mixture of management, biology, policy, and economics (both real economics and 
farmer perceptions). There are also differences in industry-wide culling rates between countries. 
The differences between countries seem to be driven by industry management decision practices 
regarding raising females for beef, tolerance of low producing cows, the value of animals at 
slaughter relative to the cost of rearing replacement heifers and the survival of young females to 
calving age and, very importantly, by the margin between milk prices and feed cost.   
 
Total U.S. national herd inventory of milking cows has been remarkably stable for the 
last decade or more, hovering slightly above 9 million cows. The average herd turnover rate on 
dairies in the United States is currently roughly 37 percent of the herd in a typical year. This 
number is driven by many factors and certainly varies farm to farm and year to year on a 
particular farm, but viewed from a national perspective, the single most important factor that 
drives the national cull rate is the number of available replacement heifers. As dairies do a better 
job of keeping heifer calves alive and of raising and breeding heifers, more heifers are available 
as replacements and one should expect the national cull rate of dairy cows to increase. Similarly, 
improved reproduction (shortened inter-calving interval), will have produce a slight increase in 
calves born per cow per year and will also impact the supply of replacement heifers. Notably, the 
wider use of sexed semen will also increase the number of replacements available unless 
producers compensate by breeding some cows with non-dairy semen and thereby hold total 
heifer births steady. 
 
 Prices of heifers sold in the open market has been increasing steadily for years, but recent 
increases have been particularly notable.  Prices for selected markets as reported by Progressive 
Dairyman magazine for May 7, 2014 show that purchase price of a new Holstein heifer is about 
$2,000 across the United States.  
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The cost of replacements on a dairy typically ranks third if properly accounted for, exceeded 
only by the cost of feed and labor. A fairly simple spreadsheet can estimate the cost of 
replacing cows with a new purchased heifer. In the example shown here, the annual cost of 
replacements on a dairy with a 33% annual exit rate, $2,000 nominal purchase price for a pre-
fresh heifer and $900 cow cull value is about $500 per cow per year, or about $1.40 per cow per 
day. Viewed in terms of milk production, at $20/cwt for milk and $6 for the cost of feed to 
support a marginal cwt of milk production, it takes about 12 pounds of milk per cow per day to 
pay the costs of the replacement program. Farms that raise their own heifers should consider the 
value of their home-raised heifers to be what they could sell them for. If they can raise them for 
less than that price, then they are profitable heifer raisers. If they spend more than the market 
price to raise a comparable heifer, then their heifer rearing enterprise loses money. 
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Large mostly western dairy accounting firms publish income statements for client dairies and 
typically break out the cost of replacements as separate line items on the report. These estimates 
are likely conservative, since some costs actually spent on heifers are bundled elsewhere in the 
accounting (machinery, utilities, etc. depending on the operation).  For 2011 – 2012, the cost per 
cow for replacements was about $250. 
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 Another approach to this question would be to simply calculate the annual depreciation of 
a cow based on the cash costs of bringing in the replacement and selling the slaughter cow 
(adjusting for death loss as above). For the same input numbers as above, this would look like 
the following and the estimate falls between the first spreadsheet estimate and the numbers from 
the accounting firm.   
 
 
 The depreciation approach assumes a straight line depreciation made at the start of the 
replacement’s first lactation. Built into the example model is the presumption that the cow will 
last for 3 years. Some cows don’t last that long, but some survive and produce for more than the 
average 3 lactations (actually about 2.7 in the U.S.). This means that some cows do not  
depreciate in a straight line fashion. They lose value more slowly than predicted at the start of 
their adult lives. A more complete model adjusts their value based on their expected lifetime 
production at a given point in their lives. Thus a cow starting her third lactation can be expected 
to have a better than zero chance of surviving that lactation and has more value than a straight 
line expectation would have predicted at the start of her adult life. For the example used in this 
calculation, a cow starting her fourth lactation is not worth only beef value ($900 in the 
example); she is worth close to $1,500. The slower rate of loss of value is driven by the 
conditional probabilities of being culled in any given lactation. Herds with lower culling rates of 
older cows retain those cows’ value better than herds with high cull rates in older cows. 
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Thus viewed from an economic perspective, there is a significant advantage if a cow’s 
productive capacity can be protected, she can be reliably be re-bred, and she survives into later 
productive lactations.  Older cows in general make more milk than younger cows and if a cow 
has more than the average number of lactations her cost as a replacement can be spread over 
more total milk production while she is part of the dairy’s herd inventory.  Events and conditions 
that reduce her productivity (milk production) or longevity reduce her time in the herd and thus 
are to be avoided where practical.  Diseases may impact either or both aspects (productivity and 
longevity) to a variable degree, but the impact on increased culling is often a major part of the 
cost of diseases. Poor reproductive performance, mastitis, and lameness are perhaps the most 
notable problems that impact the dairy by increasing premature culling.  
 
 At first blush, it certainly seems that a dairy should strive to reduce culling rate to reduce 
the cost of replacements per cow per year. Using the same inputs as the first spreadsheet, except 
using a 25% annual cull rate instead of a 33% cull rate, the results look desirable. Replacement 
costs drop from $505 per cow per year to $388; a “profit” of $117 per cow per year! 
 
 
 
 One should view this kind of calculation with a large dose of healthy skepticism. This 
extra “profit” is true only if the cow that was not culled has retained her value, i.e. has remained 
productive, avoided repeated bouts of mastitis, is not lame, and continues to breed back, etc.  
 
 
Maximizing the returns from a slot on the dairy:  
 
 Culling decisions are not made in the aggregate for a farm; the decision to cull cows is 
made on a cow by cow basis. The herd’s annual cull rate is the result of a series of individual 
cow decision. Since all cows are ultimately culled, the decision is really a largely economic 
decision to replace a “used cow” (one that has lost value) with a “new cow” (one that will make 
more profit for the dairy in the long run than the culled cow). Businesses make these kinds of 
decisions routinely as they decide to replace capital assets (taxi companies replace old taxis, 
construction companies replace old backhoes, restaurants replace old stoves). The question in 
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each a case is the same. For the dairy, the question is: “would the dairy’s long term profit be 
greater if this individual cow stays or would the long term profit be greater if she were replaced 
with a new milking heifer? (It is NOT just the next day’s milk production and profit, but rather 
long term profit that matters.) 
 
To answer that question, one ideally needs an answer to the question “What is the 
economic value of a cow on a particular dairy”?  This is perhaps best considered by setting the 
cow herself aside for a moment and thinking in terms of the “slot” on the dairy she occupies.  A 
“slot” is the capacity of the dairy to house, feed and otherwise care for a milking cow.  The 
number of slots on a dairy may be defined by actual physical spaces (tie stalls or stanchions) or 
by a more conceptual capacity defined by bunk space, milking parlor capacity, land use permit 
restrictions, or farmer preference.  If one accepts that a farm will have a certain inventory of 
milking cows, then a “slot” is one of those spaces in the inventory.  The current cow in that slot 
will produce milk and consume feed and over time will experience an increasing risk of being 
replaced until finally she is removed and a new first lactation heifer fills the slot.  The 
replacement then milks and eats, is replaced, etc.  Each day out into the future, the slot will 
produce a certain amount of milk, consume a certain amount of feed and earn a certain amount of 
income over feed costs. On some particular day, the slot will also incur the cost of replacing the 
existing cow.  The economic value of the slot is the net present value (NPV is the time 
discounted value) of that future stream of incomes over feed costs and replacement costs for that 
slot.  This concept assumes that the other important costs of running the dairy or caring for a cow 
are generally independent of which cow is in the slot. While not strictly true (a particular cow 
may cost more for disease treatment or be bred with more expensive semen) this assumption is 
fairly robust in terms of herd level economic modeling. 
 
For example, if the current cow in the slot is a young cow that produces well above the 
herd’s average, then the NPV of the slot is enhanced by her presence in it.  If she is a poor 
producer, then she detracts from the NPV of the slot by being in it. Cows that are pregnant (less 
likely to be culled) are more valuable than cows that are not pregnant.  The current economic 
value of a cow (“cow value”) is the NPV of the slot with her in it, minus the NPV of the slot 
were it instead occupied today by a new “typical” replacement heifer on that particular dairy 
(including the economic costs of bringing the replacement into the herd).   
 
Given this conceptual framework, the cull decision is essentially a question of trading the 
existing cow in the slot with a new replacement, while incurring the costs of purchase and 
earning the beef / salvage value of the exiting cow.  Neither the current cow nor the replacement 
heifer will remain in the herd forever.  Another replacement animal will eventually replace either 
one.  The most critical time period in terms of calculating this comparison in values for the slot 
between the two animals is the next several years and each animal’s milk production across that 
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period.  The replacement cost will inevitably be incurred some time in either case.  It is a matter 
of the timing of those replacement costs, not whether they will occur. 
 
Graphically, the concept looks like the following. At any time, a slot on a dairy has a 
predicted future given the particular cow filling the slot. If she stays, one can model the future 
milk income, feed cost, and future replacement events that will happen in the slot, with the 
(purple) cow staying for the moment but in the end being replaced at some series of possible 
future times. Alternatively, the cow can be replaced today with the dairy’s average replacement 
heifer (green).  This latter point is important. The long term profit of replacing the cow today 
depends on the dairy’s own predicted production and costs for an average replacement heifer on 
that dairy.  
 
existing cow 1st replacement 2nd replacement
Keep the existing cow
Replace the cow
$ NPV $$ $$ $ $
$ NPV $$ $$ $ $
Net Present Value of a “Slot” on a dairy farm:
(6 lactations shown)
CWVAL
1
6
2
21 3
3 4
4 5
5 6 >>>>
>>>>
3rd replacement
 
Thus there are two possibilities for each future lactation: a future with the existing cow 
retained in the slot (at least for the moment) and a future with a new replacement heifer. Both 
lactation series can calculate the income over feed costs depending on the cow in the slot and her 
predicted production and the cost of and probability of a replacement event. This string of 
“income over feed and replacement costs” can be discounted back to present time values and 
summed. Each sum is then the predicted financial future for the slot, either with or without the 
existing cow.  The difference between the two NPV (net present values) is the relative advantage 
(or disadvantage) of retaining the existing cow in the slot, her cow value (COWVAL).  This 
number can be calculated in any herd that uses DairyCOMP as its herd software if the input 
parameters to the model are properly set up in the program. 
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A cow’s value in comparison to a potential replacement fluctuates with milk production 
and price, slaughter value and replacement prices and depends as well on feed prices and several 
other variables, notably on her risk of being culled (sold or dead) in each lactation on that 
particular dairy.  The decision to cull an existing cow or leave her in the herd also may be 
influenced by the dairy’s supply of replacements and the dairy’s willingness to purchase 
replacements if there are none available on farm. Of these factors, milk price is most important.  
As milk price increases, the value of an existing cow decreases in relation to the replacement 
heifer.   This may not be intuitive, but it derives from the fact that cow’s value is a difference 
between the current cow and her potential replacement.  At high milk prices, the replacement 
does not need to be that much better than the current cow to justify incurring the expense of 
earlier replacement.   Translated into farm policy, this means that if high milk prices are 
anticipated to be higher over the next year or more, then the dairy should cull for production 
more aggressively.   
 
High producing cows hold their high value until some misfortune either reduces 
production (age or disease) or requires her removal (injury, failure to conceive, abortion, or 
death).  Genetically poor producing cows have a low value essentially from the outset.  Many 
should be culled as soon as their production deficiency is reliably identified.   
 
Cost of Culling 
 
When considering the cost of culling, there are actually three related questions one could ask: 
 
1. What is the cost of culling a cow at the end of her problem-free productive life after she 
has naturally declined in production with advancing age such that she has lost enough 
cow value to make it worth replacing her? 
 This would be the ideal circumstance and some cows actually achieve this, but 
most do not. 
 The cash costs of such an event would be the cost of the new replacement 
(all factors considered) minus the money earned from sale of the cow for 
beef. 
 The economic cost of such a cull would be a tidy zero. The cow’s cow 
value would have declined to being equal to the value of the new heifer in 
terms of future impact on the slot. 
2. Far more realistic: What is the cost of “prematurely” culling a cow? This is, what is the 
cost borne by the dairy because a cow has lost her future value to the dairy sooner than 
one might have desired because she got mastitis or other illness, remained open, went 
lame, got injured, etc. and the better economic decision was to replace her? 
 The cost now is the difference between her value had she not suffered one of 
these value reducing events and her salvage value as beef (or zero value if she 
died). This is the stuff of calculation of the cost of culling for diseases. This is the 
loss that all dairies try to avoid by taking good care of their cows, managing 
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transition, cow comfort, foot trimming, teat dipping, earnest estrus detection or 
synchronization, etc. 
 The simplest approach to answering this question is to use some version of 
the cow’s average depreciated value given her age and the herd’s average 
production for cows like her minus the beef price received. 
3. What is the cost of NOT culling the worst cow left in the herd? Said another way, what is 
the cost to the dairy of keeping the “worst kept cow”? 
 This is typically a cost that is invisible to the dairyman, but on many dairies it is a 
very large cost. This cost generally derives from the dairy’s desire to reduce their 
cull rate for what seems like good economic reasons and/or the dairy’s lack of 
adequate replacements and hesitance to purchase replacements in the open 
market. 
 
Estimating the cost of keeping the “worst kept cow” 
 
 In the best of circumstances, the cost of keeping the “worst kept cow” on a dairy would 
be calculated using DairyCOMP to calculate each cow’s COWVAL and simply finding the worst 
cow that was not culled. Her negative COWVAL would be the estimate of the cost of the 
mistake of keeping her. 
In practice on many dairies, the reason that a “worst kept cow” is kept is that another 
better cow suffered some event that led to her being culled and the worst kept cow was kept 
instead. The economic impact of that event and that decision could be estimated by calculating 
the difference between the value of an average cow in the herd (this presumes the bad event 
happens to an average cow) and the value of the worst kept cow.  
 
Graphically, this could be approximated (and calculated) as follows:
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 The graph shows the distribution of COWVALs across all of the cows in a large 
Holstein dairy. Some cows have very high COWVALs and some have negative COWVALs. The 
average cow in the herd has a COWVAL in this example of about $1,036 (green box). If one 
assumes the worst 10% of cows will be culled in any case (red box) and then calculates the 
average COWVAL of the cows between the worst 10% and the worse 15% of the herd, their 
average COWVAL is -$65 (blue box).  So if a calamity happens to an average cow in the green 
box and she is culled and instead a cow in the blue box is retained, the economic impact of those 
circumstances is ($1,036 – (-$65)) = a loss of $1,100 to the dairy.  It is very expensive to keep a 
bad cow just because you had to “spend” a replacement to accommodate culling an average cow 
that had to be culled. The same calculation on four large Holstein dairies shows that keeping the 
“worst kept cow” is a mistake that cows roughly $800 or more: 
 
  
 
 
 
 
If the dairy does not have access to DairyCOMP and COWVAL, an approximation of the 
same idea can be calculated based on the distribution of actual milk production for cows. Using 
the same approach of assuming the worst 10% of cows will be culled in any case and comparing 
the production of the next worst 5% to the production of the average cow, the cost of retaining a 
“worst kept cow” can be estimated.  
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Using the same four example large Holstein dairies: 
 
Cost of keeping the wrong cow
$17 milk
$0.055/lb DM
$5.60 marginal feed 
cost per cwt
Note that the cost of 
keeping the wrong 
cow is nearly 50% more 
than the cost of replacing 
a forced cull with a 
new heifer.
Beware: Cash basis shows a 
savings of $900.
 
 
 
In these examples, the cost of keeping the “worst kept cow” is on the order of $700 loss 
compared to biting the bullet and buying a replacement and culling her. These numbers are in the 
same general order of magnitude as the values calculated using DairyCOMP. In either case, the 
loss from keeping this poor cow may look like a positive cash event (the dairyman does not need 
to buy a heifer), but the real economic event is a very significant loss. 
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Conclusion 
 
 The issue of culling and economics is complex and significantly dependent on 
what question one asks and the economic conditions and constraints operating at the time of the 
decision to cull or keep a cow. In general: 
 
1. Replacement costs are a large part of the operating costs of a dairy and heifers are 
currently very expensive. Thus it makes sense for dairies to try to reduce the need to 
replace cows by taking excellent care of the cows they have. 
2. Keeping poor cows for the sake of lowering a dairy’s cull rate is a very costly mistake. 
Most dairies should cull more cows, even while working hard to reduce the need to do so. 
 
The financial objective that relates to culling is not simply a low cull rate. The 
financial goal is to maximize milk income over feed and replacement costs from each slot 
on the dairy. 
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Vaccination of transition/adult cows, with special focus on respiratory disease 
vaccination 
 
A. R. Woolums, DVM MVSc PhD DACVIM DACVM 
Department of Large Animal Medicine, University of Georgia, awoolums@uga.edu 
 
Immunity in transition cows 
 
It is well known that cows in the transition period experience significant physiologic, metabolic, 
and immunologic stress7,10,13.  If not managed, these stresses can impair productivity and 
contribute to the development of disease that can have serious impact on the cow’s quality of 
life, perhaps even leading to culling or euthanasia.  Specific impacts on the immune response 
have been characterized; some of the most important are decreased response to vaccination, 
likely resulting from decreased lymphocyte function, and decreased function of neutrophils, 
which are the cells that first defend against infection.  Thus, vaccination of cows in the transition 
period is unlikely to be as effective as vaccinations given at other times, although field trials are 
needed to clarify the practical importance of this, because useful immunity can be induced in 
cattle vaccinated 30-60 days post calving3.  Decreased neutrophil function is likely a leading 
factor contributing to the development of infectious diseases such as mastitis and metritis in the 
transition period.  Nutritional deficiencies or imbalances related to the transition period are 
important causes of immune dysfunction7,13.  At this time it appears that the leading factors 
contributing to immune dysfunction are increased blood ketones and NEFAs, and relative 
deficiency of calcium.  Deficiencies of vitamin E, selenium, zinc, and copper are also associated 
with depressed immune function in transition cows7; however, supplementation with these 
vitamins or minerals in excess of required amounts does not reliably improve immunity6.   
Careful attention to management of transition cows to prevent negative energy balance and 
hypocalcemia, and formulation of rations to ensure adequate concentration of vitamins and 
minerals, is warranted because these factors impact immune function and overall cow health.   
 
Respiratory disease in adult dairy cows 
 
Although anecdotal reports indicate that adult dairy cows can experience outbreaks of respiratory 
disease with high morbidity and an important impact on milk production, the epidemiology of 
respiratory disease in adult cows has not been well characterized.  Surveys of U.S. producers 
carried out by the USDA National Animal Health Monitoring System indicated that respiratory 
disease is the cause of 11.3% of deaths that occur in adult dairy cattle.  The relative lack of 
information regarding respiratory disease in adult cows is likely due to the fact that other 
diseases that affect reproductive performance and milk yield are of greater economic significance 
in this class of cattle. However, the few published descriptions of respiratory disease outbreaks 
confirm that the problem can on occasion be of major importance to individual herds.  The risk 
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factors for respiratory disease in adult dairy cows have likewise not been described, but it is 
reasonable to surmise that risk factors important for other classes of cattle (e.g., feedlot cattle and 
dairy calves).  Important risk factors that may contribute to the occurrence of outbreaks of 
respiratory disease in adult cows include introduction of new cattle into the group, contact with 
neighbor cattle across fencelines, or contact with youngstock; all of these groups could be a 
source of exposure to contagious respiratory pathogens.  Recent transportation and poor air 
quality in housing are likely also important risk factors.  Negative impacts of transition period 
events on immune responsiveness may also increase risk of dairy cattle for BRD; this may 
explain common anecdotal reports of dairy cows developing respiratory disease after calving.  
While the cost of respiratory disease in adult cows has not been estimated, the fact that 
respiratory disease accounts for approximately 10% of the adult cow deaths indicates that 
veterinarians and producers should be alert to signs of respiratory disease in adult cows so that 
timely treatment is implemented.  Vaccines against common viruses that can contribute to 
respiratory disase (BHV-1, BVDV, BRSV, and PI3V) should be included in the annual 
vaccination protocols so that cows maintain immunity to protect themselves and also the calves 
that consume their colostrum.   
 
Some research has indicated that cows can benefit from vaccination against respiratory 
pathogens.  In one U.S. study, first parity cows that were given a 4-way vaccine containing 
BHV-1, BVDV, PI3V, and BRSV produced significantly more milk (3.1 pounds per day) in the 
first 21 weeks of their lactation than cows receiving a 3-way vaccine the effect of vaccinating 
adult dairy cows against respiratory pathogens4.  Researchers in Sweden found that herds with 
evidence of recent BRSV infection produced less milk (1.3 pounds per day) than herds without 
evidence of BRSV infection1, which supports the concept that vaccination to prevent BRSV 
infection could improve productivity of dairy cows.  And a recent report indicated that first 
lactation milk production in Dutch dairy herds was significantly greater in herds that administred 
BRSV vaccines9.  Taken together, this research suggests that at least BRSV vaccination may 
improve cow productivity, presumably by decreasing respiratory disease, because BRSV does 
not cause disease outside the respiratory tract.   
 
Vaccinating cows to improve concentrations of antibody in calves 
 
Vaccinating cows late in gestation is sometimes considered as a mechanism to improve calf 
immunity by increasing calf serum concentrations of passively transferred antibody.  This is 
rational because antibody from the cow’s serum is transferred into colostrum in the last month or 
two of gestation.  If a cow’s serum antibody titers are increased late in gestation, it follows that 
colostral antibodies should be increased, and serum antibodies in the calf consuming the 
colostrum should be increased.  While this train of reasoning is logical, relatively little research 
has confirmed whether vaccinating cows late in gestation improves calf antibody titers, and less 
has confirmed whether the practice improves resistance of calves to disease.  Vaccination of 
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dairy cows with a commercial clostridial vaccine at 6 and 2 weeks before calving significantly 
increased anti-clostridial antibody titers in calves at 3 days of age5.  Similarly, vaccination of 
dairy cows with a Mannheimia haemolytica vaccine at 6 weeks and 3 weeks before calving 
increased antibody titers to M. haemolytica in calf serum at 2 – 7 days of age8.  In a third study, 
vaccination of beef cows with a M. haemolytica/H. somni vaccine at either 4 weeks before 
calving or 7 and 4 weeks before calving increase serum antibody titers in calves at 28 day of 
age12.  Although all of these studies showed that vaccination of cows in late gestation increased 
serum antibodies in calves, none evaluated whether disease was decreased in calves.  A small 
study evaluating whether a single dose of inactivated multivalent viral respiratory vaccine given 
to dairy cows at dry off would increase antibody titers in calves at 2 – 7 days of age showed no 
effect of vaccination10.  Two trials evaluated vaccination of late gestation cows to decrease calf 
diarrhea, with one showing a beneficial effect2, and one showing no effect14.  In summary, a 
small number of studies have shown that vaccinating cows late in gestation can improve 
antibody titers in calves; but more research is necessary to confirm that the practice can decrease 
disease in calves.   
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Five Key Factors for Transition Cow Success 
Kenneth Nordlund, DVM, Clinical Professor, School of Veterinary Medicine,  
University of Wisconsin-Madison, USA 
 
 
Abstract 
 
 Field studies of transition cow management using Transition Cow Index TM as the 
outcome variable have shown that housing constraints related to cow comfort are the major risk 
factors for fresh cow health in freestall dairies today.  Key factors to improve fresh cow health 
are provision of sufficient bunk space so that all transition cows can eat simultaneously, 
minimizing social stress or the need to establish social rank during the prepartum period, 
provision of soft bedded surfaces for standing and resting, and sizing of stalls and packs to 
facilitate the motions of lying and rising for large, mature cows, and a high quality program by 
herd personnel for early identification of fresh cows that need medical attention.    
 
Introduction 
 
 The phrase widely attributed to the management writer Peter Drucker, “If you can’t 
measure it, you can’t manage it” seems to have been especially pertinent to the development of 
our transition cow management advisory programs.  Looking back, the development of the 
measurement tool Transition Cow IndexTM (TCI) 1 has made possible our studies of transition 
cow management in the world of commercial dairies.  It has allowed us to evaluate associations 
between housing systems and fresh cow health that are not financially possible for research 
institutions.  Prior to our use of TCI, our clinical group would investigate complaints of “too 
many DA’s, deads, RP’s, etc” using primarily ration analysis techniques.  Essentially, we were 
investigating poorly defined problems using very narrowly focused tools. 
 Our approach began to change following a field survey in Wisconsin using TCI which we 
conducted in 2005.   TCI is a patented index where an expected first test-date milk yield is 
predicted for each cow in her second or greater lactation based upon the cow’s previous 
performance, and that predicted value is subtracted from her actual first test-date performance.  
In this study, TCI values are expressed in units of first test-date 305-day projected milk yield.  
While TCI is calculated at the individual cow level, herd average TCI values vary greatly 
between herds and reflect overall fresh cow health and herd management of the transition 
programs. We surveyed the transition management practices of 50 Wisconsin freestall herds with 
an average size of approximately 600 cows.  The herds represented a stratified random selection 
of herd average TCI values; meaning that equivalent numbers of herds were selected from each 
TCI category, i.e., <-1,500 lbs, -1,500 to -500 lbs, -500 to +500 lbs, etc.  Another field study of 
transition cow management practices was conducted in 22 open lot dairies in the Southwest USA 
in the summer of 2009.  From these surveys, a modest number of management practices have 
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emerged as associated with improved herd TCI scores.  Knowledge of these key transition 
management practices has informed our investigation services, our education programs for 
veterinarians and veterinary students, and an ever-increasing planning service for dairies as they 
construct new facilities. 
 The key factors associated with improved herd average TCI scores relate to provision of 
sufficient bunk space so that transition cows can eat simultaneously when fresh feed is delivered, 
minimizing social stress or the need to establish social rank during the prepartum period, 
increasing cow comfort and minimizing lameness with deeply bedded stalls or packs and 
provision of ample space within the stall to lie down and facilitate rising, and an effective 
process to promptly detect fresh cows in need medical attention. 
 While ration formulations remain a part of our investigation services, variation in dry 
cow and close-up ration formulations in our survey work has not been associated with herd TCI 
averages.  It would be a mistake to infer that ration formulations do not matter.  Rather, it may be 
that the ration formulation services provided to larger herds are generally of good quality and 
variation between well formulated transition rations is not a major determinant of overall 
transition success in our industry today. 
 
Bunk space 
 
 Sufficient space at the feeding fence for all transition cows to eat simultaneously appears 
to be the most important determinant of transition cow performance in our current industry.  In 
very practical terms, we are recommending a minimum of 30 in of bunk space per Holstein cow 
in pre-fresh and post-fresh pens for a 90-min period after fresh feed is delivered and after every 
milking.  A discussion of the studies that support this recommendation has been presented 
previously 2. 
 To determine feeding space/cow, it is important to focus on length of bunk as opposed to 
counting self-locking stanchions or headlocks. Headlocks come in a number of widths including 
24, 27, and 30 inch intervals between each unit. Our video studies show that lactating Holstein 
cows fill a row of 24 in headlocks to a maximum of 80 % at peak feeding periods.  This 80% 
maximal fill rate occurred in two and three row pens, each with various stall stocking densities, 
suggesting that the finding was independent of the number of cows per headlock.  Converting 
these numbers, it suggests that lactating Holstein cows will voluntarily fill a bunk at a spacing of 
one cow per 30 inches. It is likely that pregnant prepartum cows would take even more space 
than lactating cows. 
 These recommendations for 30 in of space assume that the pens are equipped with 
lockups or other vertical dividers between feeding spaces.  If the cows are fed at a post-and-rail 
feeder, additional space should be provided as dominant cows appear to clear subordinates 
sooner in these situations 3. 
 While we focus the most attention on bunk space in the close-up and fresh pens, the 
actual number of cows in these pens usually changes every day.  If cows are transferred into the 
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close up pen on a weekly basis, and if cows move to calving pens on a daily basis, there will be 
wide weekly swings in the number of cows in the pen.  The opposite dynamics characterize the 
fresh pens.  In addition, there will usually be seasonal changes in stocking pressure that track 
seasonal infertility and recovery by 10 months.  Because of these pen dynamics, it is more useful 
to focus on the longer term capacity of the pens. 
 The traditional approach to sizing close up and fresh pens is to calculate the average 
number of calvings per week by dividing the total number of calvings in the past year by 52 
weeks per year.  Then the average number of calvings/wk is multiplied by the target number of 
weeks in the pen.  For example, if a dairy has an average of 20 calvings per week and the 
planned duration of stay in the close up pen is 3 weeks, most planning manuals suggest that the 
close up pen should be designed to house 60 cows.  By definition, pens designed in this manner 
are overstocked half of the time. 
 We prefer to build special needs pens to accommodate the surges in numbers of special 
needs cows.  Based upon a review of a number of Midwestern herd records, we have 
recommended sizing close-up and fresh pens for 140% of the average number of calvings.  In the 
example from the paragraph above, we would recommend provision of not 60, but 84 stalls in 
the prefresh pen with an available bunk that is 240 feet in length.  Sizing these pens on this basis 
will mean that these pens are overstocked less than 10% of the time.  There are also times when 
pens sized on this basis appear to be substantially understocked, or as some would say, “grossly 
overbuilt”.  Our estimations of the impact of this practice suggest that this makes economic 
sense.  Each stall and headlock in a prefresh pen has an impact on the start of somewhere 
between 10 to 15 lactations each year.  Because of the multiplier effect on the start of the 
lactation of so many cows, it is critical that these facilities are excellent and available to all cows. 
 
Pen moves and social stress versus stable social groups 
 
 Each pen move requires that a cow familiarize herself with the surroundings, as well 
movement into a new social group also creates stress as the cow establishes rank within the 
group 4. The first 2 days after entry into a new social group are characterized by a dramatic 
increase in the number of agonistic interactions, most of them physical 5. If no additional new 
cows enter the pen, the group becomes relatively stable.  More recent work with mid-lactation 
cows has shown reduced time spent eating, increased feed evictions, and reduced milk yield 
following a pen move 6. Minimizing the number of regroupings through the transition period is 
consistent with successful transition programs. In most situations, steps to reduce any moves will 
result in improved transition performance. 
 A concept of a social turmoil profile of a pen has been described 2. In pens where cows 
enter at intermittent intervals, like a week or more, extended stays in such pens are considered 
more desirable than in pens with entries and departures every day.  Daily entry pens are 
considered to be in constant social turmoil and every effort should be made to minimize the time 
that prepartum cows spend in these pens. 
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 Cows are social animals. Isolation from the herd creates stress for a cow and separating a 
single cow into a separate calving pen for more than a couple of days appears to be a practice 
with high risks for fresh cow health.   
 
 Dry and Close-Up Pens 
 The traditional close-up pen is based upon cows entering the pen approximately 3 weeks 
prior to due date.  For reasons of convenience, cows are separated from the far-day pen and 
moved to the close-up pen once or twice each week.  In some systems, the cows deliver their 
calves in the close up pen, while in other systems they are removed to calving pens at various 
times relative to delivery.  
 Studies on the effect of the number of cows moved at one time have been conducted.  
Generally, movement of single animals should be avoided as it is believed that familiarity and 
social bonds among 3 to 5 moved animals may reduce the social stress of integrating within a 
larger group 7.  Sowerby and Polan did not find significant production differences between 
groups where between 2 and 14% of the cows were transferred at one time between lactating 
groups 8.  For reasons of both increased numbers of transferred cows and a decreased proportion 
of high turmoil days, a weekly move policy would appear to be preferable to more frequent 
entries. 
 Regardless of the frequency of new cow additions in our traditional close-up pen, each 
cow remains in a dynamic social system for a period of several weeks before calving.  New 
arrivals tend to be involved in more agonistic interactions than the current residents of the pen. 
Brakel and Leis showed that during the first day after regrouping, the average moved cow was 
involved approximately double the rate agonistic interactions of the resident cows in the pen 9. 
Moved cows will tend to maintain their rank relative to the other cows that were moved 10, but 
occupy a low rank with respect to the resident cows, even first-lactation, that already occupy the 
pen. However, the situation is sometimes more complex. Hook observed a complete reversal of 
the social rank of a group of six heifers with the removal of the high rank individual and the 
simultaneous introduction of a new heifer 11. 
 As we began applying these concepts to transition cow management, we proposed that 
the optimal transition cow pens would be based upon an all-in pen where a cohort of cows due to 
calve within a short period of time, such as a 7 to 14 day window, are assembled with no further 
additions through the calving process  2, 12.  The stable social group could be assembled at the 
time of the traditional close-up period of 3 weeks prior to calving date, or the groups could be 
assembled at dry off.  In either system, social rank would be established in the first days after the 
group is assembled, but would be followed by relatively less turmoil in the weeks that precede 
calving.  Depending on the planned duration of the dry period, there could be 4 or more separate 
cohorts of dry cows in the series of stable group pens.  The usual policy would be to periodically 
move entire pens of cohorts intact into the next pen in order to keep the cows near due date in a 
location proximal to the calf delivery facilities. 
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 Recent studies have examined the effectiveness of stable social groupings in the pre-
partum period with neutral to positive results 13, 14, 15.  Even if there is no measureable positive 
health benefit, the practice appears to bring with it several benefits for herd management.  First, 
the group is established long before calving date and even cows that deliver their calf a week or 
two prematurely are well established in a stable situation.  Second, it eliminates the additional 
lockup of dry cows and removal of close up cows from that group. Third, monitoring dry matter 
intakes of close-up pens becomes more meaningful when the cows within each pen are stable in 
numbers and stage of pregnancy. Fourth, the size of the active calving group is usually smaller 
than the conventional 3-week close up group, reducing the size of the pen to be closely 
monitored for cows beginning to deliver. 
 In practical terms, even though there is an attempt to develop stable groups at dry off, it is 
typical to need to make some modest number of transfers between pens.  Individual cows may be 
dried off early or late and may need to be transferred into a pen with cohorts more likely to calve 
at a similar time.  Likewise, as the cows deliver and are transferred out to the fresh cow pen, 
there will ultimately be a situation where there is a single cows remaining.  It is generally viewed 
as preferable to merge them with the next cohort of cows when two remain in the pen. 
 
Calving Pens 
 Calving pens can refer to either a pen to which a cow is moved hours before delivering 
her calf or it could be a close-up pen where cows enter several weeks before their anticipated 
calving date and deliver the calf within the pen.  If the calving pen has a stable social structure 
(no additions), extended stays are fine.  If new cows are continually being added, we recommend 
that the duration of stay be limited to 48 hr maximum. Clinical data from field investigations by 
the Food Animal Production Medicine group at the University of Wisconsin show dramatic 
increases in ketosis and displaced abomasums and early lactation culling of cows that stay 3-10 d 
in daily-entry group calving pens 2.  When cows are moved to calving pens on a daily basis, they 
should be selected carefully so that minimal numbers spend more than 48 hr in these high 
turmoil pens. 
 It has become common to move cows to calving pens when the feet or head of the calf 
are showing.  Moving cows to calving pens once calving has begun, commonly called “just in 
time” calving, effectively minimizes the time in high turmoil pens, but presents a new set of 
challenges.  First, it requires round-the-clock labor to check and move cows. Freestall pens can 
be designed to facilitate this practice with the construction of two-row head-to-tail arrangements 
of the stall rows. With the tails of all cows visible from the central feed alley, the observer can 
monitor each cow without walking through and disrupting the pen.  Second, workers must be 
monitored carefully in that they should not move cows into calving pens too early.  In a report on 
moving cows when parturition was imminent 17, cows that were moved when in labor but with 
only mucus showing had 2.5 times the rate of stillbirths as cows that were moved when the calf’s 
feet or head were showing.  When the close-up cows are in freestalls, there is a tendency of 
laborers to move cows into calving pens too early. By moving cows into the pens early, fewer 
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calves are born into the alleys and workers can avoid soiling their clothing when picking up 
slurry-covered calves.  This tension between worker convenience and calf health needs to be 
monitored and managed in these “just in time” calving systems. 
 Isolation pens, i.e., box stalls would appear to minimize social turmoil, but cows are 
social animals and separation from the herd is usually a stressful experience.  If cows are moved 
to individual box stalls for calving, the duration of stay should be limited to a matter of a few 
hours. 
 
Surface cushion in stalls, packs, and under shades 
 
 A loose, deeply bedded surface has emerged in our field studies as a major factor for 
improving fresh cow TCI scores.  In freestall herds, sand based stalls were associated with more 
than a 1,000 lb TCI advantage over herds with mattress freestalls.  Similarly, depth of loose 
bedding under shades emerged as a risk factor affecting herd average TCI scores in open lot 
dairies. 
 There is increasing evidence that locomotion scores increase for a substantial proportion 
of transition cows 17 and physiological mechanisms have been proposed where the same 
physiological changes that are associated with the loosening of the pelvis to accommodate 
parturition also relax the suspensory apparatus of the digit in the hoof 18.  The study of sand and 
mattress freestalls by Cook et al 19 showed that cows with elevated locomotion scores change 
their behavior on mattress stalls, but not on sand, may explain the substantial improvement in 
fresh cow performance on sand surfaces.  
 Any deep, loose surface will be an improvement over a hard surface. Mattresses covered 
with modest quantities of shavings or other materials are viewed as average, and any stall surface 
such as concrete or other firm packed materials covered with modest bedding should be 
considered a high risk to successful transitions.   
 
Amply sized freestalls, packs, and shades 
 
 A deeply bedded pack is the probably the preferred housing for close-up cows in 
confinement housing.  The guideline of 100 sq ft of space/cow 21 includes the bedded area only 
and assumes that cows have access to an external feeding alley or outside lot. If the feeding area 
is continuous with the bedded pack, the space should provide a minimum of 120 sq ft/cow with 
good bedding covering most of the area. The pack should be sized to accommodate surges in 
cow numbers as discussed in the section on bunk space above.  
  Prepartum freestalls, in particular, need to accommodate the ample dimensions of 
pregnant cows and allow for some clumsiness in their rising and lying motions.  Stalls for 
prepartum Holsteins and Jerseys should be at least 50 and 45 in wide respectively 22.  Length is 
the distance between the outer corner of the rear curb to the point where the stall surface touches 
the brisket locator.  If there is no brisket locator, the total stall length is the stall resting length.  
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This distance should be greater than 70 and 63 in for Holstein and Jersey cows respectively.  
Appropriate dimensions have been developed for cows of other breeds and various sizes 21, 22. 
 Evaluating the potential for lunge, bob, and rise should reflect assessments of 3 separate 
items in a freestall: a brisket locator that does not restrict rising motions including the forward 
swing of the front foot, freedom from impediments to the forward lunge of the head and 
shoulder, absence of bob zone obstructions, and the neck rail being sufficiently high and forward 
21, 22.  For a stall to be considered low risk for Holstein cows, the total stall length should be at 
least 9 ft long with no obstructions to forward lunge and bob.  If the stall is less than 9 ft, but the 
lower side rail is 11 in above the stall bed or less, it should allow side lunging and is considered 
an average risk for transition cows.  If the stall is less than 8 ft and has obstructions to side 
lunging, such as lower divider rails greater than 13 in above the stall bed, the stalls present major 
risks to successful transition performance.  Finally, the neck rail should be approximately 48-50 
in above the stall surface. 
 In open lot dairies, transition cow facilities should provide at least 45 square feet of shade 
per cow with loose bedding at least 3 inches deep below the shade. 
 
Effective screening program for cows needing attention 
 
 While difficult to assess, the primary determinant of the fresh cow screening and 
treatment program is the quality of the people and how much they care for the cows.  Facilities 
that allow easy restraint without exciting the cows is also critical to these programs. 
 The optimal screening programs appear to use some form of appetite assessment. The 
practices of the herdspersons of the elite transition programs in our survey study were 
remarkably similar: delivery of fresh TMR while fresh cows were being milked, palpation of 
udders for fullness while being milked, observation of cow demeanor as the cows returned to the 
pen, i.e., does she go to feedbunk or does she lie down, and an assessment of appetite and 
attitude.  Beyond process, the herdspersons in the elite herds knew and cared about the fresh 
cows under their watch. Effective screening requires both special people and facilities.  
 Back to the bunk space issue, it requires sufficient feeding space for all cows to eat 
simultaneously. Cows that do not lock-up, or cows that lock-up with suppressed appetite or signs 
of depression were examined. Other examination procedures including rectal temperature, 
observations for vaginal discharge, ketosis, displaced abomasum, lung sounds, etc., were 
conducted when primary assessments indicated further evaluation. 
 While formal screening programs in lockups for fresh cows are a desirable practice, the 
procedure needs to be efficient and not interfere significantly with the daily time-budget of the 
fresh cows.  Screening procedures that lock cows up for a period of 1 hr or less/d are considered 
optimal.  While cows are quite capable of compensating for a 1-2 hr change in routine, if lock-up 
is prolonged and in association with other stressors, such as overstocking, then the ability of the 
cow to compensate and catch-up on lying time may be exceeded. Cooper et al. showed that when 
cows were deprived of lying for 2-4 h/d, they only managed to recover approximately 40 % of 
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the lost lying time by 40 hr after the deprivation 23.  Extended lockup time adds substantially to 
the stresses of transition. 
 The location of the screening procedures has a substantial impact on the time constraints.  
If the cows have access to feed while being examined, feeding and the screening can proceed 
almost simultaneously.  Screening time at a palpation rail, for example, must be weighted as 
riskier than equivalent time in lockups over feed. 
 This antagonism between holding time and the thoroughness of the screening procedure 
puts some severe constraints on the fresh pen.   
 
 
Disclaimer 
 
 Obviously, this paper does not provide a comprehensive listing of risk factors for 
transition cows. However, the risk factors presented here are considered to be common problems 
in today’s intensively managed dairies and virtually all dairies will realize improved fresh cow 
health if they correct deficits in the areas discussed in this paper. 
 
References 
 
1. Nordlund KV. 2006. Transition Cow IndexTM.  Proc Am Assn Bov Pract Conf 39: 139-
143. 
2. Nordlund KV, Cook NB, Oetzel GR. 2006. Commingling dairy cows: pen moves, 
stocking density, and health.  Proc Am Assn Bov Pract Conf 39: 36-42. 
3. Endres MI, DeVries TJ, von Keyserlingk MAG, Weary DM. 2005. Short 
Communication: effect of feed barrier design on the behavior of loose-housed lactating 
dairy cows.  J Dairy Sci 88: 2377–2380. 
4. Hasegawa N, Nishiwaki A, Sugawara K, Ito I. 1997. The effects of social exchange 
between two groups of lactating primiparous heifers on milk production, dominance 
order, behavior and adrenocortical response.  Appl Anim Behav Sci 51: 15-27. 
5. Kondo S, Hurnik JF. 1990. Stabilization of social hierarchy in dairy cows. Appl Anim 
Behav Sci 27: 287-297. 
6. von Keyserlingk MD, Olenick MD, Weary D. 2008. Acute behavioral effects of 
regrouping dairy cows.  J Dairy Sci 91: 1011-1016. 
7. Takeda K, Sato S, Sugawara K. 2000. The number of farm mates influences social and 
maintenance behaviors of Japanese Black cows in a communal pasture.  Appl Anim 
Behav Sci 67: 181-192. 
8. Sowerby ME, Polan CE. 1978. Milk production response to shifting cows between 
intraherd groups. J Dairy Sci 61: 455-460. 
9. Brakel WJ, Leis RA. 1976. Impact of social disorganization on behavior, milk yield, and 
body weight of dairy cows.  J Dairy Sci 59: 716-721. 
25 
 
10. Schein MW, Fohrman MH. 1995.  Social dominance relationships in a herd of dairy 
cattle.  Br J Anim Behav 3: 45-50. 
11. Hook SL, Donaldson SL, Albright JL. 1965. A study of social dominance behavior in 
young cattle.  Amer Zool 5: 714. 
12. Cook NB, Nordlund KV. 2004. Behavioral needs of the transition cow and considerations 
for special needs facility design.  Vet Clinics North America Food Anim 20: 495-520. 
13. Coonen JM, Maroney MJ, Crump PM, Grummer RR. 2011. Short communication: Effect 
of a stable pen management strategy for precalving cows on dry matter intake, plasma 
nonesterified fatty acid levels, and milk production. J. Dairy Sci. 94: 2413-2417. 
14. Silva, PRB, Moraes JGN, Mendonça LGD, Scanavez AA, Nakagawa G, Fetrow J, Endres 
MI, Chebel RC. 2013. Effects of weekly regrouping of prepartum dairy cows on 
metabolic, health, reproductive, and productive parameters. J. Dairy Sci. 96: 4436-4446. 
15. Lobeck-Luchterhand KM, Silva PRB, Chebel RC, Endres MI. 2014. Effect of prepartum 
grouping strategy on displacements from the feed bunk and feeding behavior of dairy 
cows. J. Dairy Sci., Pub. online 17 March 2014. 
16. Carrier JS, Godden S, Fetrow J, Stewart S, Rapnicki P. 2006. Predictors of stillbirth for 
cows moved to calving pens when calving is imminent.  Proc Am Assoc Bov Pract Conf 
39: 158-159. 
17. Whay HR, Waterman AE, Webster AJF. 1997.  Associations between locomotion, claw 
lesions and nociceptive threshold in dairy heifers during the peri-partum period. The Vet 
Jour 154: 155-161. 
18. Tarlton JF, Holah DE, Evans KM, Jones S, Pearson GR, Webster AJF. 2002.  
Biomechanical and histopathological changes in the support structures of bovine hooves 
around the time of calving. The Vet Jour 163: 196-204. 
19. Cook NB, Bennett TB, Nordlund KV. 2004. Effect of free stall surface on daily activity 
patterns in dairy cows with relevance to lameness prevalence.  J Dairy Sci 87: 2912-2922. 
20. Bickert WG. Chapter 4. Milking Herd Facilities, in Dairy Freestall Housing and Equipment, 
MWPS-7, Seventh Edition. Ames, Iowa, Midwest Plan Service, Iowa State University, 
2000. 
21. Cook NB, Nordlund KV.  2005. An update on dairy cow freestall design.  Bov Pract 39: 
29-36. 
22. Nordlund KV, Cook NB. 2003. A flowchart for evaluating dairy cow freestalls. Bov 
Pract 37:89-96. 
23. Cooper MD, Arney DR, Phillips CJC. 2007. Two-or-four-hour lying deprivation on the 
behavior of lactating dairy cows.  J. Dairy Sci 90: 1149-1158. 
26 
 
Cow Grouping And Stocking Density During The Dry Period: What Have We Learned So 
Far? 
Marcia Endres1, Ricardo Chebel2, Karen Lobeck-Luchterhand3 and Paula Basso Silva3 
1Department of Animal Science, University of Minnesota, St. Paul 
2Department of Veterinary Population Medicine, University of Minnesota, St. Paul 
3Department of Animal Science, Graduate Student 
 
 
Introduction 
In spite of the advancements made in transition cow nutrition and management, many herds still 
have challenges during this critical period in the life of a dairy cow. Dairy cows are genetically 
driven to produce large amounts of milk in early lactation, and most cows will be in a state of 
negative energy balance during that time. Anything that affects the cow negatively, such as poor 
nutrition, housing or management, will exacerbate transition problems experienced by that cow. 
We have learned of the importance of cow comfort to improve health and productivity in our 
dairy herds. During the critical transition period, that is even more important. 
What has been suggested in terms of cow grouping during the close-up dry period? Based on 
observations from a large dairy field study, Nordlund et al. (2006) recommended that producers 
adopt a stable social grouping during the prepartum period to minimize social disruptions.  Cows 
with a similar calving date can be grouped together during the prepartum close-up period and 
stay in that pen until calving or calve in bedding pack pens.  During this time no new cows are 
added to the pen until all to most of the current animals have calved.  One disadvantage of the 
stable pen management system is the need for additional pens which increases building cost.  
Cook (2009) recommended sizing the pens to accommodate 140 percent of the average weekly 
calving rate with the stable pen management.  At times, pens will be underutilized while a few 
remaining cows are awaiting parturition.   
What about stocking density? In a study designed to evaluate the effects of a dietary supplement 
on productive and health parameters of prepartum cows and heifers housed together, it was 
observed that for every 10 percentage unit increase in stocking density above 80% of headlocks 
there was a 1.5 lb/day decrease in milk yield among first lactation cows (Oetzel et al., 2007). 
Based on this and a small number of other studies, a common industry recommendation is to 
limit stocking density for close-up cows to 80% or providing 30 inches of feedbunk space per 
cow.  
Grouping Management Strategy Study 
A study that examined a stable pen management versus a dynamic pen did not find a difference 
on the number of displacements from the feed bunk, dry matter intake, plasma NEFA 
concentrations and milk production up to 30 DIM (Coonen et al., 2011).  In that study, 
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approximately one cow was added at a time to a small pen with only 10 cows. Additionally, 
cows in their study calved in the dry cow pen.  It was unknown whether these results would be 
similar to movements of small groups of cows into a larger pen with cows then being moved to a 
calving pen as they near parturition (like feet showing or ‘just in time’ calving), similar to 
conditions experienced on large commercial dairies.  Therefore, we conducted a study to 
compare a stable social group or all-in-all-out (AIAO) during the close-up prepartum period with 
a traditional pen management (TRD) that had weekly entrance of new animals in a large dairy 
setting.   
The study was conducted at a large commercial dairy farm (6,400 lactating animals) in south-
central Minnesota. For health and performance data we used a total of 567 primiparous and 
multiparous non-lactating Jersey cows allocated to 6 replications using two pens at a time, one 
for each treatment (AIOA or TRD). For the behavior portion of the study we used a total of 224 
cows allocated to the two treatments with two replications. Cows assigned to the TRD treatment 
were moved to the study pen as a group of 44 cows and weekly thereafter groups of two to 15 
cows were moved to the study pen to reestablish stocking density (~92% of headlocks). Cows 
assigned to the AIAO treatment were moved to the study pen in groups of 44 cows, but no new 
cows entered the AIAO pen until the end of the replicate. At the end of each replicate, a new 
TRD and AIAO group started but pens were switched.  
When cows demonstrated signs of calving, farm personal moved the cows to an individual box 
stall.  Video observation ceased when the cows left the dry period treatment pens. At day 1 post-
calving, cows were moved into a freestall pen with 240 stalls and 260 headlocks stocked at 100% 
based on the number of stalls for 21 days. Plasma NEFA concentration was measured weekly 
from day −18 (prior to calving) to day 24 post-calving and plasma β-hydroxybutyrate (BHB) was 
measured weekly from day 3 to 24 post-calving. Cows were examined on days 1, 4, 7, 10 and 13 
post-calving for diagnosis of uterine diseases, and had their ovaries scanned by ultrasound on 
days 39 and 53 post-calving to determine resumption of ovarian cycles. 
Average stocking density was reduced for the AIAO (71.9%) treatment compared with the TRD 
(86.9%) treatment. Treatment did not affect the incidences of retained fetal membranes (TRD = 
10.9, AIAO = 11.6%), metritis (TRD = 16.7, AIAO = 19.8%), and acute metritis (TRD = 1.7, 
AIAO = 3.6%). Concentrations of NEFA (TRD = 80.4, AIAO = 62.9 µmol/L) and BHB (TRD = 
454.4, AIAO = 446.1 µmol/L) were not different between treatments. Percentages of cows that 
resumed ovarian cycles by d 39 (TRD= 70.8, AIAO = 63.1%) and 53 (TRD = 90.1, AIAO = 
90.2%) were not different between treatments. Similarly, treatment had no effect on rate of 
removal from the herd (TRD = referent, AIAO [(adjusted hazard ratio (95% confidence interval)] 
= 0.85 (0.63, 1.15)) or rate of pregnancy (TRD = referent, AIAO = 1.07 (0.88, 1.30)). Finally, 
treatment did not affect energy-corrected milk yield (TRD = 75.9, AIAO = 75.7 lb/day).  
Behavioral observations showed a treatment × week interaction for mean daily number of 
displacements from the feed bunk.  The TRD treatment had more displacements from the feed 
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bunk during weeks 1, 3, and 5 (P < 0.05) than AIAO treatment, whereas there were no 
differences between the treatments during weeks 2 and 4.  There was a treatment by week 
interaction for daily feeding times (P < 0.001).  Cows housed in the AIAO treatment spent 39 
fewer minutes per day eating during week 1 than TRD treatment.  During week 2 of the study, 
the AIAO treatment had a 25 minutes/day longer average daily feeding time than the TRD 
treatment (P < 0.05), with a tendency of longer feeding time during week 3 of the study (P = 
0.054).  There were no differences between the treatments in feeding times during weeks 4 and 
5. There were no differences in maximum feed bunk occupancy occurring at fresh feed delivery 
(0500 h) with 64.9 and 68.6% of cows eating at that time for the TRD and AIAO, respectively 
(Figure 1).  In general, the AIAO treatment had a greater percentage of feed bunk occupancy 
during periods of low feeding activity. 
 
 
Figure 1. Percentage of cows eating at the feed bunk over a 24-h period for a stable (AIAO, all-
in-all-out) or a weekly entrance of new animals (TRD, traditional) pen management during the 
close-up prepartum period. Significant differences in percentage eating were found for feeding 
periods 0030-0450, 1320-1330, 1650, 1720, 2200-2210, and 2320-2340 h. 
 
The AIAO grouping strategy had fewer displacements from the feed bunk than the TRD and this 
was evident during all weeks of the repetition except during week 2 and 4 when the treatments 
did not differ.  Even when accounting for changes in stocking density the AIAO treatment still 
had a lower displacement rate than the TRD treatment.  The AIAO cows spent fewer minutes 
eating daily than the TRD cows during week 1, whereas having a longer feeding time during 
week 2.   
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Our results (with Jersey cows and approximately 92% feed bunk stocking density) indicate the 
AIAO treatment reduced negative social behaviors and altered daily feeding times. However, the 
AIAO treatment did not improve health, metabolic, reproductive, or productive parameters 
compared with the TRD treatment. 
 
Stocking Density Study 
We hypothesized that increasing prepartum stocking density would affect behavior and 
metabolic parameters and consequently affect health and performance of dairy cows in early 
lactation. The objectives of study were to determine the effect of increasing prepartum stocking 
density from 80% (80SD) to 100% (100SD) of headlocks on the day of regrouping on behavior, 
metabolic, health, reproductive, and productive parameters of dairy cows. We used 324 animals 
(141 first-calf heifers, 183 cows) for the 80SD treatment and 404 animals (173 first-calf heifers, 
231 cows) for the 100SD treatment.  
Daily average stocking densities based on number of headlocks (80SD = 74.1%, 100SD = 
94.5%) and stalls (80SD = 80.8%, 100SD = 103.1%) were different (P < 0.01) between 
treatments; therefore our goal of a 20% unit difference in stocking density between treatments 
was achieved. 
Incidences of peripartum diseases were not different between 80SD and 100SD treatments 
(Table 1). Similarly, incidences of DA and mastitis in the first 60 d post-calving were not 
affected by treatment. Percentages of cows with locomotion score > 2 at 0, 35, and 56 days post-
calving were not different between treatments. Similarly, treatment did not affect the likelihood 
of cows being removed from the herd within 60 d post-calving. The rate at which cows in the 
100SD treatment were removed from the herd [adjusted hazard ratio (AHR) (95% CI) = 1.02 
(0.75, 1.38)] did not differ from that of cows in the 80SD treatment. The mean intervals from 
calving to removal from the herd were 258.3 days for the 80SD treatment and 262.5 days for the 
100SD treatment. 
Body condition score was not affected by treatment. Concentration of NEFA (80SD = 251.5, 
100SD = 245.9 µmol/L) was not different between treatments. Similarly, concentration of BHB 
(80SD = 508.2, 100SD = 490.9 µmol/L) was not different between treatments. 
The percentage of cows characterized as cyclic by 35 and 45 DIM was not different between 
treatments. Similarly, the likelihood of cows being inseminated in estrus and the DIM at first 
postpartum AI were not different between treatments. The percentage of cows diagnosed 
pregnant 31 and 66 days after first and second postpartum AI was not different between 
treatments and the incidence of pregnancy loss between 31 and 66 days after first and second 
postpartum AI was not different between treatments. The interval from first to second 
postpartum AI and the DIM at second postpartum AI were not different between 80SD and 
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100SD treatments. Average daily milk, fat and protein yield from calving to 155 DIM were not 
different between treatments. 
 
Table 1. Effects of prepartum stocking density (80SD vs. 100SD)1 on incidence of postpartum 
health disorders, lameness, and removal from the herd within 60 d postpartum 
Items 
 
80SD,%  
 
100SD,%
 
AOR (95% 
CI) 
 
P–
value 
Retained fetal membranes 5.1  7.8 1.55 (0.78, 3.07) 
0.19 
Metritis 21.2  16.7 0.71 (0.46, 1.09) 
0.11 
Acute metritis 9.9  9.4 0.87 (0.45, 1.66) 
0.64 
Vaginal purulent discharge at 35 ± 3 
DIM 
5.8  7.9 1.41 (0.65, 3.05) 
0.35 
Mastitis up to 60 DIM 2.9  4.6 1.94 (0.70, 5.39) 
0.18 
DAs up to 60 DIM 1.0  0.7 0.76 (0.10, 5.80) 
0.78 
Locomotion score > 2 at 1 ± 1 DIM 0.6  0.0 0.26 (0.02, 3.19) 
0.27 
Locomotion score > 2 at 35 ± 3 
DIM 
3.8  2.6 0.66 (0.25, 1.75) 
0.37 
Locomotion score > 2 at 56 ± 3 
DIM 
3.5  2.1 0.56 (0.12, 2.69) 
0.44 
Removed within 60 DIM 6.1  5.1 0.84 (0.38, 1.83) 
0.63 
180SD = cows housed in prepartum pens with 80% target headlock stocking density (38/48); and,  
100SD = cows housed in prepartum pens with 100% target headlock stocking density (48/48). 
 
Body condition score was not affected by treatment. Concentration of NEFA (80SD = 251.5, 
100SD = 245.9 µmol/L) was not different between treatments. Similarly, concentration of BHB 
(80SD = 508.2, 100SD = 490.9 µmol/L) was not different between treatments. 
The percentage of cows characterized as cyclic by 35 and 45 DIM was not different between 
treatments. Similarly, the likelihood of cows being inseminated in estrus and the DIM at first 
postpartum AI were not different between treatments. The percentage of cows diagnosed 
pregnant 31 and 66 days after first and second postpartum AI was not different between 
treatments and the incidence of pregnancy loss between 31 and 66 days after first and second 
postpartum AI was not different between treatments. The interval from first to second 
postpartum AI and the DIM at second postpartum AI were not different between 80SD and 
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100SD treatments. Average daily milk, fat and protein yield from calving to 155 DIM were not 
different between treatments. 
The 100SD treatment resulted in a greater number of displacements from the feedbunk than the 
80SD treatment independent of parity. Feeding time was reduced for nulliparous animals in the 
80SD treatment compared with the 100SD treatment but feeding time was greater for parous 
animals in the 80SD treatment than those in the 100SD. Interestingly, stocking density had no 
effect on lying time of prepartum cows but first-calf heifers in the 80SD treatment had more 
lying bouts per day than first-calf heifers in the 100SD treatment.  
In conclusion, increasing average daily stocking density by 20 percentage units (from 80 to 
100%) affected behavior of prepartum animals. On the other hand, changes in behavior 
associated with elevated stocking density had no impact on metabolic status or health, 
reproductive, and productive parameters. 
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Introduction 
 
There seem to be multiple recommendations for best management of transition cows.  The reality 
is that some strategies work on some farms but not others.  Rather than make broad sweeping 
recommendations, a guideline for transition cow investigations is perhaps more revealing.  
Unraveling the cause of transition cow problems is a complex task.  The “cause” will always be 
multifactorial, meaning that there will be multiple components that have ultimately contributed 
to the eventual problem.  Since this is the case, often investigations will stop once one issue has 
been identified.  A solution or remedy directed at this one particular issue may fail to alleviate 
the big problem. The investigation will then continue until the next issue is identified. This 
process is frustrating and lacks a systematic approach.  Recognizing the multifactorial nature of 
disease and using a systematic approach to problem solving can help with making a more 
efficient diagnosis and often remedy the transition cow problem much faster. 
 
Overview of the diagnostic approach   
 
The diagnostic approach to herd  investigations is similar to that used at the individual animal 
level.  In our Ruminant Health Management group at the Ontario Veterinary College in Guelph 
we teach our students the hypothetico-deductive approach to making a diagnosis.  This method 
consists of generating and refining diagnostic hypotheses through the presenting complaint, 
history, general inspection, routine exam, and clinical tests.  This method can be applied to 
individual sick animals or to herd level problems.  In addition, employing the W-5 (what, who, 
where, when, why) criteria is critical to solving and correcting transition cow issues.  Since most 
transition cow problems are multifactorial, the challenge is to identify and address the most 
critical factors contributing to the problem.  Finally, monitoring outcome success is an important 
and often overlooked part of the herd investigation.  
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Understanding the diagnostic process  
(figure adapted from Dr. Ken Bateman, OVC, University of Guelph) 
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W5 of case investigation: what, who, where, when, why? 
 
Presenting complaint 
 
This is the “What”.  The first step is to define the problem and the second step is to determine if 
it is actually a problem or not.  Calculate incidence of the problem using the appropriate 
denominator (correct population at risk) and compare this number to the target, goal, or industry 
standard.  Finally, the problem timeline needs to be addressed.  Is it a new problem or an old 
problem?  Establish the timeline by tracking the disease incidence over time.  For example, the 
problem  is new this year, new this month, new this week, etc.  Note, good records make this 
process much easier. 
 
For example:  A herd complains of fresh cow problems in the last month.  A fresh cow problem 
could be anything (hypocalcemia, subclinical ketosis/fatty liver, metritis, mastitis, etc).  Is the 
problem related to a specific disease or disease syndrome?  Is it happening right at calving, 
within the first two weeks, or later?  Is the problem either restricted to or absent from a parity 
group.  We don’t expect to see milk fever problems in first parity heifers for example.  
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Develop the history 
 
Who – Demographics: parity, birth or calving cohort, purchased or home, etc 
Where – specific location of occurrences (pen, barn, etc) 
When – calendar time (dates) and animal time (DIM) 
Why – The most difficult to understand – What has changed?  Asking what has changed  is 
usually not very fruitful.  However, asking specific questions about what might have changed 
can be useful.  Have you switched to a new bunker silo?  Has the labour situation recently 
changed?  Have you had an increase in the number of cows calving?, etc. 
 
General inspection (Step back and look – Big picture things) 
 
The general inspection consists of understanding the cow perspective on the farm.  Walk through 
the cows from two perspectives:   
1. A day in the life of a cow (understand the farm routines) 
2. A year in the life of a cow (understand management flow from dry to calving to lactation) 
Look for anything that is obviously wrong such as: 
- Empty Bunks 
- Overcrowding 
- Low or High BCS 
- Cow comfort issues 
- Fine rations or Sorting 
- Etc. 
 
Routine examination 
 
The routine exam may revisit areas found to be abnormal in the general inspection.  This is a 
systematic approach to walking through the farm that addresses issues relative to the Diagnostic 
Hypotheses.  This would usually include: 
 
- Cows – evaluation of BCS, grouping, frequency of group changes, etc 
- Feeds and Feeding- assessment of  quality, particle size, diet changes, etc. 
- Bunk Management – gathering information on frequency of feeding, push-ups, etc 
- Headlocks and Stalls – assessment of overcrowding 
- Environment – Ventilation, Stall design, Bedding, Floors, Water 
- Management Routines and Prevention/Treatment Measures 
- etc 
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Clinical tests 
 
This is the final stage of the diagnostic process that is used to help confirm or refute Diagnostic 
Hypotheses.  Tests might include the following:  post mortems, serum or blood parameters, 
forage and VFA analysis, rumen pH, urine pH, etc. 
 
Concept of the tipping point 
 
It is important to understand that all disease syndromes have complex causes and therefore are 
multifactorial in nature.  In working through any investigation, there will most likely be several 
factors that have been identified as problems and many of those will have existed for sometime.  
This leads to the question, why now?  Often it is the combination of these factors that is 
important, with the last change tipping the problem over into an obvious and large clinical issue.  
The challenge is to identify the key factors that need to be addressed to tip the scale back toward 
health. 
 
 
Key strategies for prevention of metabolic disease 
 
Management guidelines 
 
Since metabolic disease problems occur in early lactation, recommendations for prevention have 
focused on the nutritional management of the dry and transition cow.  The goals of the transition 
diet (specifically designed to prevent energy-related metabolic disease) are to maximize dry 
matter intake and to provide optimal energy density (Oetzel, 1998).  Avoidance of ketogenic 
feedstuffs and the reduction of overconditioning cows in late lactation and the early dry period 
have also been suggested as aids in prophylaxis.  Strategies for prevention of hypocalcemia are 
similar with the added attention to potassium concentration in the diet and possibly managing the 
diet through dietary cation anion balance.  The challenge with adding anionic feed additives to 
the dry cow diets is the attention to detail required for successful implementation.  Many farms 
simply do not have the management skills or resources to effectively utilize this tool and in fact 
may limit intake by over-acidifying the dry cow diet.  Maximizing dry matter intake and 
maintenance of a consistent intake through the last three weeks prior to calving is likely the 
hallmark of a successful transition cow program.  High fibre diets have been effective in 
reducing excess energy in dry cow diets, particularly in the early dry period, and for maintaining 
rumen fill.  These diets are aimed at reducing the risk of increased insulin resistance, a suspected 
cause of so-called ‘Type-II’ ketosis.  However, the main advantage of these diets is limiting 
energy in the first half of the dry period.  One must remember that NDF still limits intake; so 
excessively high NDF diets can reduce or limit dry matter intake.  Additionally, challenges exist, 
in smaller herds in particular, in the compromise between the correct energy concentration in the 
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diet for a one group dry cow diet, that still allows a smooth transition onto the lactating cow diet.  
Too high an energy concentration and cows gain weight and the ‘low-energy’ dry cow diet is 
ineffective.  Too low an energy concentration and there could be rumen adaptation issues onto 
the highly digestible and higher starch lactating cow diet.  For these reasons, many herds have 
reverted back to a more traditional two-group dry cow approach, but with renewed emphasis on a 
low energy far-off diet.  Osborne (2003) indicated that a dry matter intake (DMI) of less than 12 
kg per cow per day in the last 3 weeks prior to calving substantially increased the subsequent risk 
of subclinical ketosis postcalving (Odds Ratio 5.7, p < 0.05).  Achieving group DMI targets 
above an average of 12 kg per cow per day should be a goal for the close-up group.  More 
important than ration formulation and ration ingredients, close attention should be paid to cow 
comfort and environmental issues.  These factors include but are not limited to adequate pen 
space or stall space per cow, adequate feed bunk space, sufficient and comfortable bedding, 
adequate water supply and minimization of heat stress.  The frequency of group changes and 
additions to groups around transition is a huge stressor that should be limited as much as 
possible.  Recent research has identified several social stressors as being associated with 
suboptimal herd performance.  These include mixing of primiparous and multiparous cows 
precalving, and the use of individual calving pens. 
 
Prevention tools 
 
In addition to good nutrition, certain products have been found beneficial in improving transition 
cow health  Propylene glycol has been used successfully for the prevention of subclinical ketosis 
(Emery et al, 1964; Sauer et al, 1973).   Several studies have been conducted with varying doses 
and durations of treatment.  Generally, propylene glycol is more effective when drenched 
because the bolus effect provides a stronger insulin response (Christensen et al, 1995).  A dose in 
the range of 300 to 500 ml (or 10 to 16 oz) is sufficient when started on the day of calving and 
administered for 3 days. 
 
A series of meta-analysis of monensin studies in lactating dairy cattle has clearly demonstrated 
that monensin through the transition period reduces BHBA, NEFA, acetoacetate; and increases 
glucose (Duffield et al, 2008a,b,c).  These important improvements in metabolic parameters 
result in a reduced risk of clinical disease, including reductions in the incidence of displaced 
abomasum, clinical ketosis, and mastitis.  In addition, cows administered monensin through 
transition produce significantly more milk, particularly those cows at highest risk of ketosis.  
Monensin delivered through a controlled-release capsule is more consistent at improving 
metabolic indicators of health.  For most effective control the monensin capsule should be 
administered precalving (ideally 3 to 4 weeks prior to expected calving). 
 
Rumen protected choline has been shown to influence liver glycogen and triglyceride 
(Piepenbrink and Overton, 2003), but not in all studies (Zahra, 2004).  A topdress of 56 g per day 
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of rumen protected choline during the transition period did not affect BHBA, NEFA, liver 
glycogen or liver triglyceride.  However, milk production was significantly increased in choline 
treated cows and this effect was more pronounced in cows that were over-conditioned. 
 
Several studies have demonstrated an improvement in dry matter intake through transition with 
the feeding of yeast products.  However, impacts on metabolic parameters and clinical health 
outcomes have not been investigated to date. 
 
Conclusions 
 
Herd variation for metabolic disease incidence problems are wide and herd level risk factors are 
poorly described.  However, herd level risk factors most likely involve combinations of 
management, feed quality and nutritional programs, cow comfort, environment, and other 
variables that influence dry matter intake.  Routine monitoring programs for subclinical ketosis is 
beneficial on many dairies and can serve as an important early warning system for metabolic 
disease problems, as well as a highly useful means of assessing effects of management or 
nutritional changes..  
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Introduction 
 
Metabolic monitoring has its roots in metabolic profiling developed in Compton, England in the 
1970’s. Since that time automated laboratory machines and enzyme kits to measure a battery of 
serum or blood constituents is widespread and commonplace. However, ease of sample 
collection and submission is not justification for conducting metabolic herd testing. Serum 
analytes have more value when used appropriately in the diagnostic process or as part of a 
specific objective in herd monitoring programs for metabolic disease. Profile testing should not 
be used in place of other more appropriate procedures, such as ration evaluation and physical 
examinations. The transition cow represents the target with the most utility for metabolic 
profiling. 
Most periparturient abnormalities have some metabolic element as a component of the sufficient 
cause of clinical disease. Negative energy balance, fat mobilization and subsequent elevations in 
ketone body concentrations play a contributing role in the expression fatty liver syndrome, 
clinical ketosis, and abomasal displacement. A negative energy balance during transition may 
also increase the risk of retained placenta, metritis, and mastitis through impaired immune 
function. In addition to energy balance, nitrogen balance and calcium homeostasis are disrupted 
through parturition. Therefore, several biochemical parameters may be useful for monitoring 
cows in the transition period. 
 
Objectives of metabolic monitoring 
 
There can be two main objectives for conducting serum metabolite testing in periparturient cows. 
Although these objectives may overlap, it is worth stating them for clarity. 
1. Cow-level interpretation – There is a problem with this cow and treatment and/or further 
examination may be warranted. 
2. Herd-level interpretation - There is a potential problem with the current herd management 
that needs to be investigated. 
 
Cow and herd level interpretation can be conducted with the same samples but they differ in that 
we are differentiating between an individual or group problem. In our opinion the group 
interpretation is the strongest reason for conducting the tests regardless of whether it is an 
ongoing monitoring program or a herd-problem investigation. 
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Serum metabolites to consider 
 
Circulating concentrations of non-esterified fatty acid (NEFA) and -hydroxybutyrate (BHBA) 
measure the success of adaptation to negative energy balance. NEFA reflects the magnitude of 
mobilization of fat from storage. BHBA indicates the completeness of oxidization (“burning”) of 
fat in the liver. Ketone bodies (BHBA, acetone and acetoacetate) are intermediate metabolites of 
oxidation of fatty acids; as the supply of NEFA to the liver exceeds the ability of liver to 
completely oxidize the fatty acids to supply energy, the amount of ketone body production 
increases. Ketone bodies can be used by muscle as an alternative fuel source to glucose, sparing 
glucose for milk production (Herdt, 2000a). However, ketone production does not result in as 
much net energy release as does complete oxidation of fatty acids. Additionally, increasing 
concentrations of ketones are thought to suppress feed intake. 
Glucose is the primary metabolic fuel, and is absolutely required for vital organ function, fetal 
growth, and milk production. In dairy cows, the massive energy demand to support milk 
production is partly met through gluconeogenesis. Glucose  concentrations are under tight 
homeostatic control. Therefore, although glucose has a central role in metabolism, it is a poor 
analyte for monitoring or investigating herd problems (Herdt, 2000b). However, recently we 
have discovered a poetenial role for glucose measurement in assessing  treatment  success. 
Ketotic cows with low serum glucose responded to parenteral supplementation with vitamin B12 
in addition to oral propylene glycol,. However, ketotic cows with normal serum glucose did not 
benefit from the B12. Aspartate aminotransferase is an enzyme that becomes elevated with cell 
damage and may be elevated in cows with fatty liver disease. Although there have been 
associations between AST and subsequent occurrence of displaced abomasums (Geishauser et al, 
1997), the test lacks both sensitivity and specificity. For energy balance NEFA and BHBA are 
the best two measures. 
Calcium demand is tremendous immediately postpartum and monitoring serum calcium in cows 
less than a week following calving may have some utility but before or beyond this time period, 
it makes no sense to measure calcium. Low serum calcium concentrations (subclinical 
hypocalcemia) have been linked with increased risk of early lactation culling (Duffield et al, 
2005; Roberts et al, 2012) and reduced milk production (Chapinal et al, 2012). Effective 
cowside monitoring of both NEFA and calcium is currently not available because of the absence 
of cowside tests for either analyte. 
Haptoglobin is an acute phase protein that becomes elevated under situations of inflammation. 
However, this inflammation indicator is non-specific and could reflect for example dystocia, 
mastitis, metritis or displaced abomasum. However, despite its non-specific nature haptoglobin 
may also have utility for monitoring transition cows. 
Currently the strongest data exists for the use of NEFA and BHBA testing in transition dairy 
cows. The remainder of this article will focus on these two analytes. 
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Key associations of NEFA and BHBA with health and performance in transition dairy cows are: 
 
 High NEFA in the 2 weeks before calving is associated with 
o 2 to 4 times increased risk of LDA (Cameron et al, 1998; LeBlanc et al, 2005) 
o 1.8 times increased risk of retained placenta (RP) (LeBlanc et al 2004) 
o 2 times increased of culling before 60 days in milk (DIM) and 1.5 times increased 
risk of culling over the whole lactation (Roberts et al, 2012) 
o Decreased milk production (Ospina et al, 2011; Chapinal et al, 2012) 
o Deceased reproductive performance (Ospina et al, 2011) 
 Subclinical ketosis (BHBA > 1200 – 1400 mol/L) in early lactation is associated with 
o 3 to 8 times increased risk of LDA (Geishauser et al, 2000b; LeBlanc et al 2005; 
Duffield et al, 2009) 
o increased risk of metritis (Duffield et al, 2009) 
o Decreased probability of pregnancy at first AI (Walsh et al, 2007; Ospina et al, 
2011) 
o Decreased milk production (Duffield et al, 2009; Ospina et al, 2010; Chapinal et 
al, 2012) 
o Increased duration and severity of mastitis (Suriyasathaporn, 2000) 
 
 
 
Monitoring NEFA and BHBA 
Cow selection 
By most definitions, the theoretical testing period for transition cows would extend from 3 weeks 
prior to calving until 3 weeks after calving. Practically however, the most important time 
periods are: 
1. during the last week prior to calving 2. within the first 2 -3 weeks after calving. 
 
 
Precalving 
 
It is unusual for cows to develop subclinical ketosis (SCK) precalving because the etiology of the 
condition depends on the homeorhetic drive for milk production. However, cows in an energy 
deficit precalving will start mobilizing energy reserves in the final week before parturition. This 
can be measured via serum or plasma NEFA. The challenge for this precalving sample is 
predicting when the animal is going to calve. In the past, establishment of a serum bank and 
retrospective submission of samples relative to calving have been recommended. However, 
recent data suggests that assessment of samples obtained within a week of expected calving is a 
practical approach that seems to provide meaningful information (Leblanc et al, 2005). 
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Postcalving 
 
A routine ketone testing program should commence after calving. The primary risk period for 
SCK is the first month of calving. The first 2 weeks postcalving is the time of peak incidence. 
In addition, the median days from calving to diagnosis of clinical ketosis and displaced 
abomasum is around 11 days. Thus, in order to try to prevent subclinical disease from becoming 
clinical disease (if that is possible), cows must be identified earlier. For these reasons, a SCK 
monitoring program should focus on the first 2 to 3 weeks of lactation. 
 
Required sample size 
 
The number available for testing depends on the herd size. For both BHBA and NEFA it is 
proportion rather than mean measurements that are important.  A good thumb rule for evaluating 
a herd is to interpret data based on 12 samples. This is based on the following: 
in a close-up or fresh cow group of up to 500 cows, assuming that detection of a prevalence of 
subclinical disease of 10% is the threshold of interest, to have 75% confidence of detecting the 
problem, 13 samples are required (Dohoo et al, 2003). Oetzel (2004) proposes using 12 samples 
for simplicity of interpretation. In small herds, this may require repeated sampling over time. 
 
 
 
Test selection 
 
NEFA 
 
This test should only be used precalving on samples obtained within 1 week of expected 
parturition. It can be used within 2 weeks of parturition based on the work of Ospina et al (2011) 
but a lower cutpoint of around 0.3 mmol/L should be used. The data for NEFA is frequently 
right skewed and thus averages can be very misleading.  One suggested threshold is 0.5 units/L. 
In recent work, cows within 1 week of calving with serum NEFA above this threshold were at a 
3.5 times greater risk of subsequently developing a displaced abomasums (Leblanc et al, 2005). 
Whole herd interpretation is best made by calculating a proportion of cows above a threshold 
value, however, there is limited data on an appropriate goal for this parameter. In a muti-herd 
1060 cow study near Guelph, 30% of cows were above 0.5 U/L during the last week prior to 
calving (Leblanc et al, 2005). 
The potential of NEFA as a monitoring tool is further highlighted by research conducted at the 
Elora dairy research center (Osborne, 2003). Of 136 transition cows evaluated, 24 had BHBA 
concentrations 1400 mol/L of serum in the first week post-calving (17.6%). There was a 
significant association between NEFA concentration in the week prior to calving and BHBA 
concentration in the first week post-calving. A nearly 5-fold increased risk of SCK was noted 
when the NEFA concentrations in the week before calving were greater than 0.7 mmol/L 
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(OR=4.8, P=0.04) (Osborne, 2003). Our research group currently uses 0.4 mmol/L for cows in 
the last week prior to expected calving and 0.3 mmol/L for cows two weeks prior to expected 
calving for all research and herd investigations. 
 
BHBA 
 
In contrast to NEFA, serum BHBA should only be used postcalving. The first two weeks are the 
primary risk period for subclinical ketosis, defined by a serum concentration of 1400 umol/L 
BHBA or greater (Duffield, 2000). A reasonable goal is to have less than 2 cows per 10 with 
BHBA above 1400 umol/L in the first 2 weeks post-calving. Many other studies have been 
conducted and threshold ranges can be defended between 1000 and 1400 umol/L depending on 
study and outcome. Our research group has been using 1200 umol/L for recent research and for 
herd investigations. 
 
Sample Handling 
 
Both NEFA and BHBA can be measured with either plasma or serum. Both analytes are subject 
to interference with hemoglobin in the sample, thus, hemolysis will artificially elevate 
measurements and should be avoided. Both NEFA and BHBA are subject to changes relative to 
time of feeding. Samples meant to compare performance on the same farm should be obtained at 
approximately the same time of day. The most severe swing in values in our experience appears 
to be with NEFA with highest values obtained just before first feeding. Therefore it is best to 
sample herds at some point after the first feeding of the day. NEFA concentrations could be 
slightly falsely elevated if serum were not separated within 12-24 h of blood collection, or if 
samples were not kept chilled (Stokol and Nydam, 2004). Serum can be kept frozen for at least 1 
month without affecting NEFA results. Samples should be collected from the tail vein (not the 
milk vein) and ideally chilled, separated within a few hours, and then frozen or shipped chilled 
for receipt at the laboratory within 1 to 2 days. However, delay of up to 24 hours for separation, 
and kept at room temperature for 1 day or refrigerated for < 3 days does not substantially affect 
results (Stokol and Nydam, 2004). 
 
 
 
Cowside tests 
 
Milk ketone tests 
 
Most milk ketone tests measure acetone and acetoacetate through a reaction with nitroprusside 
which causes a colour change from white to pink or purple. These tests in general are poorly 
sensitive in milk (<40%) but highly specific (>90%) (Duffield, 1997; Geishauser et al, 1998). 
One exception is the milk ketone test that measures BHBA. It was once marketed in Europe as 
“Ketolac BHB”, in Japan as “Sanketopaper”, and in Canada as “Keto-Test”.   This test has a 
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much higher sensitivity in milk (>70%) and reasonably good specificity (>70%, up to 90%) 
(Oetzel, 2004). This is a semi-quantitative test that allows choosing a lower threshold for 
screening to increase sensitivity, and a higher threshold for diagnosis to increase specificity. 
 
Urine ketone tests 
 
The urine ketone tablet tests are based on the same nitroprusside reaction as the milk powder 
ketone tests. These tests are highly sensitive (approaching 100%) but are poorly specific. Thus, 
they are great tests for ruling out subclinical ketosis with a negative test result. However, their 
use overestimates a subclinical ketosis problem because of a high probability of false positive 
reactions (see Table 1). However, recent work out of Minnesota suggests that a 5 to 10 second 
interpretation using the Ketostix in urine is just as accurate as the Keto-Test in milk (Carrier et 
al, 2005). 
 
Blood tests 
 
The human device Precision  Xtra glucometer used with the ketone strips (sold by Abbott 
laboratories) is a highly accurate cowside test for measuring blood BHBA. Several studies have 
documented Sensitivies and Specificities in the low to mid 90’s. This test is the most accurate 
cowside test available. 
 
Selection and interpretation of cowside tests 
 
There are two possible actions resulting from screening a group of fresh cows with a ketone test. 
One action might be to treat all positive animals with the goal to prevent subsequent 
development of clinical disease. In this case, a high predictive value of a positive test is desired 
so that normal animals are not unnecessarily treated. The second action might be to compare the 
percent of positive reactors to a goal for determining the effectiveness of either the transition 
ration or some prophylactic measure in reducing the incidence of subclinical ketosis. In this 
situation, the apparent prevalence is the parameter that actually would be used.  Note from Table 
1 that the urine Acetest tablet would substantially overestimate the prevalence of subclinical 
ketosis, while the Ketocheck test would grossly underestimate the prevalence. Despite a 
consideration of the inherent sensitivity and specificity of these two tests, their utility for group 
level decision making is questionable. The Acetest might be used with an adjustment in the 
apparent prevalence goal. The Ketocheck test is simply too insensitive to be useful. However, 
both the Keto-Test and the Ketostix are useful tests for group level monitoring and for individual 
animal identification. 
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Table 1. Use of cowside ketone tests in screening programs for identifying 
subclinical ketosis. 
 
Test 20% Prevalence 40% Prevalence 60% Prevalence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(blood)  using  1.4 
mmol/L 
PV +ve: Predictive Value of a pos. test result. PV –ve: Predictive Value of a neg. test result. 
 
 
 
Other tests 
 
Herd disease records 
 
Herd records are important tools for monitoring the incidence of periparturient disease. 
However, it is highly critical that standardized disease definitions are in place to allow 
comparison from year to year and from farm to farm. Producers should set goals for the 
minimizing the incidence of metabolic disease. Herd consultants should periodically review 
herd performance relative to these goals. In addition, intervention levels should also be 
considered. Several diseases are associated with increasing age and this must be taken into 
account when assessing herd performance. For example, in monitoring and comparing herd 
incidence of milk fever and clinical ketosis, it is important to stratify this by parity. A high 
proportion of first lactation animals will likely give a herd a much lower incidence of milk fever 
and clinical ketosis, since risk increases with age. 
 
Dry matter intake 
 
Clearly cows that are mobilizing NEFA precalving will have suboptimal dry matter intake. In a 
recently completed project, serum BHBA concentration in the first week post-calving was 
significantly associated with the average DMI in the week prior to calving (Osborne, 2003). 
There was a significant increase in the risk of subclinical ketosis (BHBA 1400 mol/L of 
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blood serum) if the DMI was below 12 kg/d (OR=5.7, P=0.05) in the three weeks prior to 
calving. If the DMI in the week prior to calving was below 11 kg/d, there was a greater risk of an 
animal developing subclinical ketosis in the first or second week post-calving (OR=2.9, P=0.05) 
(Osborne, 2003). Thus, measuring and monitoring the dry matter intake in the close-up group 
every week has utility. However, beware of group demographics relative to time of expected 
calving and parity, which can influence these parameters dramatically. Fresh cow intakes are 
generally less useful because we are primarily interested in the intakes of cows within the first 
three weeks postcalving. If a fresh cow group exists, it is often composed of cows that may be 
several months postcalving. Larger farms are more likely to have more useful opportunities for 
measuring dry matter intake because of the ability to group cows into parity and smaller days in 
milk windows. 
 
DHI test day data 
 
Since milk fat and milk protein percentages are altered in sublinical ketosis, these parameters 
have been investigated for their utility in defining subclinical ketosis. Among all protein and fat 
parameters, a protein to fat ratio of 0.75 was the best test for diagnosing subclinical ketosis, at 
the cow level, in a Canadian study (Duffield et al, 1997). However, the protein to fat ratio was 
not a good test overall, having a sensitivity of 58% and a specificity of 69%. There is good 
European data that supports using milk acetone measured in routine DHI samples. A big 
problem with both this and protein to fat ratio is the frequency of sampling.  Subclinical ketosis 
is prevalent in the first few weeks postpartum. However, DHI testing frequency is typically 
every 30 to 40 days. Thus the interval of sampling is too infrequent to hold great utility. 
However, the incorporation of milk acetone into in-line sampling methodology that could be 
done daily, holds tremendous promise. 
 
Identifying high risk herds 
 
Herd incidence of certain diseases may be useful to decide whether a herd has a problem with 
subclinical ketosis. Using data from a 25 herd study conducted in Guelph in 1995/1996, the 
median cumulative herd incidence of subclinical ketosis was 41% in the first two months 
postcalving, which crudely broke down into a threshold of 20% in week 1 and week 2 
postcalving. Summary data for each herd from each cows first DHI test postcalving was used to 
assess the protein to fat ratio as a test at the herd level for classifying a herd as a high or low 
incidence herd for subclinical ketosis. If more than 40% of cows in the herd at 1st DHI test had a 
protein to fat ratio of less than or equal to 0.75, those herds were likely to be problem herds. 
This test had a sensitivity of 69%, and a specificity of 83%. Although more work needs to be 
done on herd level indicators of subclinical ketosis, herd level protein to fat ratios appear to be 
better indicators of herd level issues than individual cow protein to fat ratios are of identifying 
cows with subclinical ketosis problems. 
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Additional analysis indicates that the herd incidence of displaced abomasum is positively 
associated with the probability of a herd having a high incidence (>20% in the first 2 weeks of 
lactation) of subclinical ketosis. In addition, if herds had greater than 10% of transition cows 
with a BCS 4.0 at 3 wks precalving, that herd was extremely likely to have a problem with 
subclinical ketosis. 
 
Economics of monitoring 
 
For the herd level monitoring interpretation, the savings achieved is in identifying a problem 
sooner rather than later, since nearly all problems will eventually be identified. A conservative 
estimate of the economics of a biweekly program suggests that a routine monitoring program 
would payback if one major problem was identified earlier than traditional means every 4 to 5 
years. The economics of individual cow testing depends on the efficacy of treatment, accuracy 
of the test, cost of the therapy and prevalence of disease.7 
 
Conclusions 
 
Given the cost of subclinical ketosis, the fact it is a common problem in early lactation, and the 
strong association with clinical disease, monitoring programs for subclinical ketosis during the 
first few weeks of lactation may be warranted. There are several cowside tests for subclinical 
ketosis available. However, only Ketostix in urine, Ketotest in milk, or Precision Xtra for blood 
have sufficient documented accuracy to be useful in a monitoring program.The appropriate 
design and frequency of a subclinical ketosis monitoring program will depend on the purpose of 
the program and the frequency of disease  within the herd. Utilization of a technician in 
peripartum monitoring programs might be a way to ensure compliance and benefit both the herd 
and the veterinarian. 
 
Selected references 
 
1. Cameron, R.E.B., P.B. Dyk, T.H. Herdt, J.B. Kaneene, R. Miller, H.F. Bucholtz, J.S. Liesman, 
M.J. Vandehaar, and R.S. Emery. 1998. Dry cow diet, management, and energy balance as risk 
factors for displaced abomasum in high producing dairy herds. J. Dairy Sci. 81:132-139. 
 
2. Carrier, J, S. Stewart, S. Godden, J. Fetrow, and P. Rapnicki. 2004. Evaluation and Use of 
Three Cowside Tests for Detection of Subclinical Ketosis in Early Postpartum Cows. J. Dairy 
Sci. 87:3725–3735 
 
3. Chapinal N, Carson M, Duffield TF, Capel M, Godden S, Overton M, Santos JE, LeBlanc SJ. 
The association of serum metabolites with clinical disease during the transition period. J Dairy 
Sci. 94: 4897-4903, 2011. 
47 
4. Chapinal, N., Carson, M.E., LeBlanc, S.J., Leslie, K.E., Godden, S., Capel, M., Santos, J.E.P., 
Overton, M.W., Duffield, T.F. The association of serum metabolites in the transition period with 
milk production and early-lactation reproductive performance. J. Dairy Sci. 95: 1301-1309, 
2012.4.Duffield, T. 2000. Subclinical ketosis in lactating dairy cattle. Vet. Clin. North Am. Food 
Anim. Pract. 16:231-253. 
 
5. Duffield, T.F., Kelton, D.F., Leslie, K.E., Lissemore, K., Lumsden, J.H. Use of test day milk 
fat and milk protein to predict subclinical ketosis in Ontario dairy cattle. CVJ 38:713-718, 1997. 
 
6. Duffield, T.F. DVSc dissertation, University of Guelph, 1997. 
 
7. Dohoo, I., W Martin, and H. Stryhn. 2003. Veterinary Epidemiologic Research. AVC Inc., 
Charlottetown, PEI, Canada. 
 
8. Geishauser T et al. J. Dairy Sci. 81: 438-443, 1998. 
 
9. Geishauser, T., Leslie, K., Kelton, D., Duffield, T. Monitoring for subclinical ketosis in dairy 
herds. Compendium of Continuing Education. 23: s65-s71, 2001. 
 
10. Geishauser, T., K. Leslie, J. Tenhag, and A. Bashiri. 2000a. Evaluation of eight cow-side 
ketone tests in milk for detection of subclinical ketosis in dairy cows. J. Dairy Sci. 83:296-299. 
 
11. Geishauser, T., K. Leslie, and T. Duffield. 2000b. Metabolic aspects in the etiology of 
displaced abomasum. Vet. Clin. North Am. Food Anim. Pract. 16:255-265 
 
12. Herdt, T.H. 2000a. Ruminant adaptation to negative energy balance. Vet. Clin. North Am. 
Food Anim. Pract. 16:215-230. 
 
13 . Herdt, T.H. 2000b. Variability characteristics and test selection in herd-level nutritional 
metabolic profile testing. Vet. Clin. North Am. Food Anim. Pract. 16:387-403. 
 
14. LeBlanc, S.J., K.E. Leslie, and T.F. Duffield. 2005. Metabolic Predictors of Displaced 
Abomasum in Dairy Cattle. J. Daiy Sci. 88:159–170. 
 
15. Oetzel G.R. 2004. Monitoring and testing dairy herds for metabolic disease. Vet. Clin. N. 
Amer. Food Anim. 20:651-674. 
 
16. Osborne, T.M. MSc dissertation, University of Guelph, 2003. 
 
17. Ospina, P.A., , D.V. Nydam, T. Stokol, T.R. Overton Associations of elevated nonesterified 
fatty acids and β-hydroxybutyrate concentrations with early lactation reproductive performance 
and milk production in transition dairy cattle in the northeastern United States. Journal of Dairy 
Science Vol. 93, Issue 4, Pages 1596-1603, 2010. 
48 
18. Roberts, T., Chapinal, N., LeBlanc, S.J., Kelton, D.F., Dubuc, J., Duffield, T.F. Metabolic 
parameters in transition cows as indicators for early-lactation culling risk. J. Dairy Sci. 95: 
3057-3063, 2012. 
 
19. Stokol, T. and D. Nydam. 2004. Effect of anticoagulant, storage temperature, and time on 
non-esterified fatty acid and beta-hydroxybutyrate concentrations in dairy cows. Vet. Clin. Path. 
33:190 (abstr.) 
 
20. Suriyasathaporn, W., C. Heuer, E.N. Noordhuizen-Stassen, and Y.H. Schukken. 2000. 
Hyperketonemia and udder defense: a review. Vet. Res. 31:397-412. 
 
21. Walsh, R.B., Walton, J.S., Kelton, D.F., LeBlanc, S.J., Leslie, K.E and T. F. Duffield The 
Effect of Subclinical Ketosis in Early Lactation on Reproductive Performance of Postpartum 
Dairy Cows. J Dairy Sci 2007 90: 2788-2796. 
 49 
 
Success factors for transition cow management and lameness  
Dr. Gerard Cramer, DVM, DVSc, Associate Professor Dairy Production Medicine 
University of Minnesota, St. Paul MN 
 
 
 
Introduction 
 
Lameness is a painful, costly disease that affects productivity of cows through its effect on milk 
production, culling and reproductive performance. In addition, lameness is also a major animal 
welfare concern as it is highly prevalent and more importantly recognizable by consumers. 
 
Worldwide, clinical lameness prevalence estimates range from 20 to 30%. Estimates of the 
prevalence of foot lesions found at hoof trimming are much higher however, ranging from 40 to 
70% of cows (Cramer et al, 2008). Types of lameness due to foot lesions can be broadly 
categorized into infectious (digital dermatitis heel horn erosion, foot rot) and hoof horn (ulcers, 
white line disease, hemorrhage). Although infectious lesions are the most common type of 
lesions in most herds, hoof horn lesions are far more costly due to their effects on milk 
production and culling. 
Economic losses due to hoof horn lesions are difficult to quantify yet it is becoming apparent that 
cows affected with hoof horn lesions are usually cows with higher production potential and 
production losses start prior to a lameness diagnosis. Typical production losses for cows with 
hoof horn lesions range from 200-500 kg plus these cows are also at increased risk of culling. 
Infectious lesions, on the other hand, do not appear to have an association with long term 
productivity and are a source of short term inconvenience. 
Fortunately for the dairy industry the knowledge exists to prevent and reduce the impact of 
lameness. This knowledge can be summarized into the following four success factors. 
1. Low infection pressure 
2. Good horn quality and hoof shape 
3. Low forces on the feet 
a. Good cow comfort 
b. Good cow flow 
4. Early detection and prompt effective treatment of lame cows. 
 
The implementation of these success factors requires a management approach that is similar to 
the dedication and approach most producers have to improving udder health. 
The focus of this paper is on the process of the developing a foot health program. It will outline a 
foot health program that can be used to reduce the level and impact of lameness. This foot health 
program has 6 components and focuses on controlling the major risk factors for both infectious 
and hoof horn lesions. The reader will find specific recommendations absent. This is due to the 
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fact that recommendations are farm specific and on farm particulars need to be considered.  
 
Foot Health Programs Components: 
 
1. Record and use lesion data from lame cow trimmings. 
2. Find lame cows early and treat them quickly and appropriately. 
3. Provide a housing environment that ensures cows’ feet are comfortable, clean and dry. 
4. Disinfect and clean cows' feet regularly. 
5. Ensure cows' feet have a proper weight bearing surface through proper hoof trimming by 
a trained individual. 
6. Minimize metabolic stresses especially nutritional and transition problems. 
 
1. Record and Use Lesion Data: 
 
The recording and use of foot lesion data from clinically lame cows is necessary to the 
development of a foot health program and for its continuation. This data is necessary for the 
design of a good foot health program as knowledge of the type and stage of lactation of the 
lameness event allows the prevention program to be tailored to the specific farm instead of being 
created for the average dairy farm. Continued recording of foot lesion data allows for the 
monitoring and adjusting of the foot heath program as farm dynamics evolve. 
Recording of foot lesion data starts with the person doing the hoof trimming. Ideally this person 
records lesions in a standardized manner to allow proper communication between the hoof 
trimmer and the farm's advisory team. It is equally important that the person who identifies and 
treats the lame cows uses the same terms as the person doing the routine preventative hoof 
trimming so there is continuity in the data collected.  
The recording of foot lesion data does not have to be complicated. At minimum what is recorded 
is the cow's ID, the date, the lesion and the treatment.  Additional data on location and size of the 
lesion is of lesser value from a monitoring perspective and should not become an impediment to 
the recording of the necessary basic information.  Regardless of recording method it is necessary 
that this data gets entered into the on-farm software to allow both cow and herd level 
interpretations to be made.  
 
2. Find and Treat Lame Cows Early 
 
The second and probably the most important part of the foot health program is to create a 
protocol for early detection and treatment of lame cows.  It is quite likely that the dairy industry 
can make the biggest change in lameness prevalence by addressing the lack of detection and 
treatment of lameness.   
The primary reason to focus on the detection and treatment of lameness is to improve the well-
being of the cow.  Compared to a cow with either metritis, mastitis or a displaced abomasum, the 
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time between noticing her as diseased and implementing a treatment is usually delayed 
considerably for the lame cow.  Typical comments are: “Oh we’ll see how she does in a couple of 
days”, or “The hoof trimmer is coming in a month”, or “Maybe a shot of antibiotics will fix that 
swollen claw”. Since lameness can quickly develop into a chronic disease, early intervention will 
result in reduced duration of pain, quicker return to productivity and reduced chance of 
chronicity. 
 
3. Clean, Dry and Comfortable 
 
This part of the foot health program focuses on the key risk factors for both infectious and hoof 
horn lesions.   
 
3.1 Clean and Dry 
The organisms responsible for digital dermatitis, foot rot and heel horn erosion are anaerobic 
bacteria that thrive in wet and moist conditions.  For this reason the major focus to control 
infectious foot lesions should be to ensure that the cow’s feet are clean and dry. No amount of 
foot bathing will overcome an environment where the cow’s feet are constantly coated with 
manure. In free stalls manure and wetness are a fact of life, but measures can still be taken to 
reduce exposure to wetness by ensuring proper drainage and avoiding pools of water in cow 
traffic areas.  
Although alley scrapers are used a as labour saving device, several research studies have shown 
an association with increased scraping frequency and higher prevalence of digital dermatitis 
(Cramer et al., 2009).  Therefore scraping of alleys should occur at times when cows’ feet do not 
get coated by a “tsunami” of manure several times a day and timing of the scraper should be such 
that the majority of cows are not standing in the alleys when it is running. For barns with slats, 
alleys should also be scraped and robotic alleys scrapers are an effective way to accomplish this. 
Currently, no clinical trial has been done with alley scrapers to prove the association with digital 
dermatitis prevalence. However, observations of feet in alley scraper barns reveal a thicker coat 
of manure on the front wall of the claw as opposed to manually scraped barns. This thicker coat 
would create a more anaerobic environment. 
One of the best ways to reduce exposure to manure is to increase the amount of time cows spend 
lying down in a well bedded stall. A well bedded stall will serve 2 functions; entice the cow to lie 
in it thereby reducing manure exposure and the secondly the deep bedding will have a cleansing 
action on the feet.  
 
3.2 Comfortable 
Hoof horn lesions such as sole ulcers, white line lesions and hemorrhage are caused in a large 
part by movement of 3rd phalanx (P3) in the claw capsule. The downward movement of P3 
causes compression of the corium resulting in the production of inferior horn. Depending on 
several factors including the duration and extent of movement by P3, different lesions can 
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develop. The exact cause of the movement of P3 is still open for debate, but enzymes and 
mediators that act on ligaments and the thickness of the digital cushion are all thought to play a 
role.  
For hoof horn lesions to develop there needs to forces acting on the corium both from the 
exterior and interior of the claw. This occurs when a cow is standing as there is pressure exerted 
on the corium by P3 and a counter pressure by the surface she is standing on.  
The major risk factor that should be controlled for to prevent hoof horn lesions is standing time.  
Any change to cows' environment that can be made to reduce standing time is going to result in 
less lameness as it removes weight bearing from the corium. This focus on cow comfort needs to 
go beyond the stall and needs to consider the cow's time budget to discover areas of “avoidable” 
standing time.  A typical cow stands approximately 12 hours/day split up in 2.7 hrs for milking, 
4.3 hrs for feeding 2.5 hrs for time in the alley and 2.7 hrs in the stall (Gomez and Cook, 2010).  
Herd level factors that influence standing time on individual farms include parlour and holding 
pen size, stocking density, social make up of groups, heat abatement strategies and management 
procedures like fresh checks and synchronizing programs.  
The above factors all affect standing time and are in addition to the effects that stall design and 
management has on standing time. There is not enough space to address each of these factors 
individually in this paper.  For the design a foot health program the impact of each of these 
factors needs to considered and if short comings are identified, additional management efforts 
will need to be devoted to other areas to compensate for these deficiencies. 
 
4. Disinfect and Clean Regularly 
 
Once we have addressed the cleanliness of the cow's feet, the reality is that most herds still 
require the regular use of a proper footbath to clean and disinfect feet.  For most herds it is likely 
not the type of product used that is responsible for the lack of apparent control of infectious 
lesions. Even though there are few clinical studies to prove the efficacy and economics of most 
current foot bath products, no product will be effective if it is not used regularly and effectively. 
What defines regular is likely herd dependent but just like teat dipping is a standard practice 
twice daily, foot bathing should be standard practice daily on all free stall herds.  
A good footbath protocol starts with thinking of a footbath as a preventative tool, similar to teat 
dipping, and not as a treatment tool. There is a role for antibiotics in footbaths as a treatment 
solution, however in most cases these should be short term in nature and not used on an ongoing 
basis. 
On most farms digital dermatitis control would improve if footbaths were run more frequently. 
Does this mean that there needs to be disinfectant in the bath every time? Potentially, but even 
having a cow walk through a footbath with water alone or with a small amount of soap will have 
a cleansing action and over time remove the caked manure on the foot. This cleansing will result 
in a cleaner foot so when a disinfectant is used 3-5x/week, it will be more effective. An 
additional benefit to running cows through a footbath more frequently is that the footbath 
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becomes part of the cow’s routine and running a footbath does not automatically mean a longer 
milking time. 
For a footbath to be effective we need contact time with the disinfectant and in this case more is 
better. One way to do this is to increase frequency of use, but the other way is to increase the 
number of “dips”. If we consider the length of a cow and how far apart her feet are and then 
watch cows walk through a six foot footbath, it becomes obvious that 6 foot footbaths were 
meant for the cow to stand in and not to walk through. Recent work out of Wisconsin has shown 
that over 60% of cows get less than 2 “dips” in a 6 foot footbath (Cook, 2010 pers. comm.). 
Unfortunately, 6 foot long footbaths are common both in the portable and permanent concrete 
form. The ideal footbath is at least 8-10 feet long, narrow (20 inches) and have a minimum of 2 
feet high side walls to avoid cows stepping on the side and to keep solution in the bath. 
Minimum water depth should be at 4-6 inches. Higher curbs at the entrance and exit of the 
footbath will force cows to take more steps again increasing the number of “dips”. To create 
good cow flow through the footbath the ideal location for a footbath is not in the return lane but 
in the area that links the parlour to the barn. If this is not possible, then having the footbath at the 
very end of the return alley will allow for better cow flow out of the parlour. 
Spraying the cows feet either in head locks or in the parlour is an alternative to a regular foot 
bath program but can quickly become a labour issue. Whether spraying or foot bathing, it is 
important to remember to include dry cows and heifers in the control program. 
 
5. Proper Balanced Weight Bearing 
 
Hoof trimming plays an important preventative role in a foot health program.  In most of our 
current housing environments an imbalance is created between horn growth and wear. 
Preventative hoof trimming attempts to remove the excessive growth and redistribute the forces 
that occur within a cows' foot to avoid excessive pressure on the sole ulcer location. Several 
excellent texts exist that describe a functional trimming technique based on the method 
developed by Dr. Toussaint Raven. The basis of this method is to transfer weight bearing from 
the overgrown outside claw to the inside claw and to create a flat weight bearing surface to walk 
on. Unfortunately, no research exists that evaluates different trimming techniques. However, for 
any trimming method the goal of trimming is to prevent or treat lameness and any horn that is 
removed from cows' foot should meet these criteria.  
Hoof trimming should only be done by trained personnel, who have knowledge of the anatomy 
of the foot as it is possible to do a lot of damage with improper hoof trimming. The required 
frequency of hoof trimming is cow dependent but in most cases cows should be examined at 
least twice a year. An examination does not necessarily mean that the foot is trimmed, but twice a 
year a judgment is made about the length and shape of her feet. Some chronically lame cows will 
benefit from more frequent trimmings and if a hoof trimmer makes regular visits to a herd this 
becomes much easier to implement. 
 
 54 
 
6. Minimize Metabolic Stress 
 
The transition period is also a time of great metabolic stress thus in a foot health program this 
time period cannot be ignored.  Recent work has shown increased standing behaviour in 
transition cows not only leads to traditional transition cow problems, but also foot lesions 
(Proudfoot et al., 2010) This finding provides another reason to treat transition cows properly 
and ensure they go through a stress free calving. Additionally, recent work from Cornell has 
shown that there is a relationship between body condition score, the thickness of the digital 
cushion and lameness rates.  Although still preliminary, these findings suggest that cows that lose 
a lot of body fat during early lactation also lose a lot of shock absorptive capacity in their feet 
increasing their risk of lameness (Bicalho, et al., 2009). 
Traditionally nutritional factors and nutritionists have received a lot of the blame for lameness 
problems in herds. Surprisingly, the evidence in the literature for a causal relationship between 
subclinical acidosis and lameness is very weak. Based on our current understanding of the digital 
cushion, suspensory apparatus and the effect that mediators and enzymes have on the tissues and 
structures inside the claw, the diet the cow eat is likely less important than how she eats it.  
Factors that increase standing time or create periods of slug feeding such as available bunk 
space, consistency and quality of the actual feeds and ration delivery, and behavioural factors 
likely play a bigger role than the actual “paper” ration. 
To minimize metabolic stress and to promote proper horn growth and integrity the role of trace 
minerals and vitamins in a foot health program cannot be ignored. Whilst supplementing trace 
minerals should be considered in most herds it is important to remember that to gain the maximal 
benefit from these products they should be fed in the dry period and during lactation. 
 
Conclusion 
 
By focussing on lameness success factors the dairy industry can prevent lameness from 
becoming a major animal welfare issue. The implementation of this knowledge requires a 
dedicated management approach to foot health similar to the one that exists for udder health. The 
keys of this program are to detect and treat lame cows early, focus on clean, dry and comfortable 
feet that are regularly disinfected and evaluated, and ensure cows do not experience metabolic 
stresses at key periods in their lactation. Following these principles will reduce lameness levels 
in the dairy industry but will require a concerted effort by all sectors of the industry including 
producers, hoof trimmers, veterinarians, nutritionists, researchers, dairy supply companies, and 
contractors. 
 
Note 
This paper was adapted from a paper presented at the Western Canadian Dairy Seminar in 2010. 
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KEYNOTE: Values, Trust and Science, Building Trust in an Age of Radical 
Transparency and Unbridled Social Media 
Charlie Arnot, APR, President, CMA & CEO 
Center for Food Integrity, 2900 NE Brooktree Lane, Suite 200, Gladstone, MO 64119 - USA 
Tel: (816) 880-0204, Charlie.arnot@foodintegrity.org  
 
 
 Every organization operates with some degree of social license. Once lost through a 
single event or a series of events, it is replaced by social control (legislation, regulation).  
 Today’s operating environment mandates transparency. In this age of social media, food 
system stakeholders must develop new models for authentic engagement. 
 A truly sustainable system is ethically grounded, scientifically verified and economically 
viable. 
 
The social license to operate 
 
Every organization, no matter how large or small, operates with some level of social license.  A 
social license (illustrated below) is the privilege of operating with minimal formalized 
restrictions based on maintaining public trust by doing what’s right.  You are granted a social 
license when you operate in a way that is consistent with the ethics, values and expectations of 
your stakeholders.  Your stakeholders include customers, employees, the local community, 
regulators, legislators and the media. 
 
Once lost, either through a single event or a series of events that reduce or eliminate public trust, 
social license is replaced with social control.  Social control is regulation, legislation, litigation 
or market action designed to compel you to perform to the expectations of your stakeholders.  
Operating with a social license is flexible and low cost.  Operating with a high degree of social 
control increases costs, reduces operational flexibility and increases bureaucratic compliance. 
 
 
 
Source: CMA Consulting, LLC 
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A U.S. case in point - Arthur Anderson and Enron.  Prior to the collapse of Enron, public 
accounting firms operated with a fairly broad social license.  The accounting industry had 
established the Financial Accounting Standards Board to regulate the implementation of 
Generally Accepted Accounting Principles by Certified Public Accountants.  The accounting 
industry created a structure for self-regulation based on the expectations of their stakeholders 
which included investors, banks, the Securities and Exchange Commission, financial media and 
others. 
 
Stakeholders relied on the industry to operate in a way that maintained public trust and in return 
the public was willing to grant accountants broad social license.  The Enron debacle cost the 
accounting profession its social license.  That single event was the tipping point that compelled 
Congress to replace the social license of the accounting profession with the Sarbanes-Oxley Act, 
a law that requires extensive reporting and verification of financial information by publicly 
traded companies.  According to research by Foley & Lardner, the average cost for a public 
company to comply with Sarbanes-Oxley is between $10 and $15 million per year.  Those are 
costs that could have been returned to shareholders as dividends, or reinvested in research and 
development. 
 
The question then becomes, what can be done to maintain public trust that grants the social 
license and protects freedom to operate? 
 
Transparency is no longer optional 
 
Today, anyone with a cell phone is a cinematographer. Research over the past four years clearly 
indicates that consumers increasingly go online to look for information to answer their questions 
about food. The power of social media to change the food system became clear in 2012 when 
concern over Lean Finely Textured Beef (LFTB) by a mommy blogger in Houston created an 
online firestorm that drove leading branded food companies, restaurants and grocery chains to 
eliminate a product that was supported by science. 
 
In today’s age of unbridled social media, food system stakeholders have to develop new models 
for authentic engagement.  Growing skepticism about food safety and the use of technology fuel 
online communities that are raising issues and making their voices heard with increasing volume 
and frequency.  In this dynamic new environment (illustrated below) producers, processors and 
distributors are inextricably linked to their customers and NGOs interested in food issues. The 
question for food companies is no longer “will you be transparent,” but rather, “how will you 
protect your social license in an age of radical transparency?” 
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New models for building trust 
 
The food system has an incredible challenge and opportunity ahead.  By mid-century we have to 
more than double food production to meet the needs of more than 9 billion people.  We have to 
produce more food by the end of this century than we’ve produced in the last 10,000 years 
combined.  To meet that challenge we have to embrace new models of public engagement that 
build and maintain public trust and our social license to operate. 
 
We need stakeholders who control social license to understand that while our systems have 
changed and our use of technology has increased, our commitment to doing what’s right has 
never been stronger.  We need to be able to verify our claims with objective science and we have 
to be able to continue to operate profitably if we want to survive.  We need to adopt systems and 
practices that are ethically grounded, scientifically verified and economically viable. (model 
below) 
 
 
Source: CMA Consulting, LLC 
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It is only by achieving and maintaining this balance that we can create systems that are truly 
sustainable.  Each side of the sustainability triangle has stakeholders focused on maintaining the 
strength of that side, even at the expense of maintaining balance.   There may be times when 
stakeholders have to look beyond short term self-interest to foster truly sustainable food systems.   
 
If food system practices are not ethically grounded they will not achieve broad-based societal 
acceptance and support.  If they are not scientifically verified there is no way to evaluate and 
validate the claims of sustainability, and if they are not economically viable they cannot be 
commercially sustained.  For a system to be truly sustainable, it has to be ethically grounded, 
scientifically verified and economically viable. This model encourages stakeholders to look for 
balance in an effort to find true sustainability.   
 
Ethically Grounded 
 
Those who focus on ethics want food system practices that are consistent with the shared values 
of compassion, responsibility, respect, fairness and truth.  They want to ensure that our 
increasingly sophisticated and technologically advanced food system doesn’t put profits ahead of 
ethical principles and that science is not used as moral justification.  When this side of the 
triangle is out of balance, critics claim there is no scientific basis for the claims being made and 
that the ethical demands will jeopardize the economic viability of the system. 
 
Source: CMA Consulting, LLC 
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Scientifically Verified 
 
Those with a primary interest in scientific verification are data driven.  They want specific, 
measurable, and repeatable observations to provide the basis for their objective decisions.  They 
believe science can provide the insight and guidance necessary to make reasonable 
determinations about how food systems should be managed.  When this side of the triangle is out 
of balance, critics claim the organization is relying on science while ignoring ethical 
considerations and that research may be done and recommendations made without consideration 
of the economic impact. 
 
Economically Viable 
 
Those responsible for the “bottom line” are focused on profitability.  They work every day to 
respond to demand, control costs and increase efficiency to maximize the return on investment.  
They have to manage the increasingly complex demands of competing in a global marketplace 
with volatile commodity markets and ruthless competition.  When this side of the triangle is out 
of balance, critics claim profits outweigh ethical principles and that business decisions are made 
without the benefit of scientific verification, placing those decisions at risk when questioned by 
those who value validation. 
 
If we can’t operate a system that maintains a balance of practices that are ethically grounded, 
scientifically verified and economically viable, it will collapse. That collapse may subject 
producers, processors, restaurants or retailers to undue pressure that includes consumer protests 
or boycotts, unfavorable shareholder resolutions, uninformed supply chain mandates, regulation, 
legislation, litigation or bankruptcy. 
 
Maintaining balance is never easy.  Success demands an increased level of communication and 
engagement and willingness to look for solutions that are ethically grounded, scientifically 
verified and economically viable for each segment of the food system.  Only by working with 
stakeholders across the food chain can we maintain the integrity of the sustainable system. 
 
Conclusion – It’s about trust 
 
As we increase both the distance most consumers have from farming, food processing and the 
level of technology we implement in food production we have to dramatically improve our 
ability and commitment to build trust with our customers and other stakeholders who grant social 
license.   This will require a new way of thinking, a new way of operating and a new way of 
communicating.   
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To be successful we have to build and communicate an ethical foundation for our activity and 
demonstrate our commitment to practices that are ethically grounded, scientifically verified and 
economically viable. 
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Writing Protocols 
Mike Apley, DVM, PhD, DACVCP 
Department of Veterinary Clinical Sciences, Kansas State University 
 
 
Protocol sophistication will vary depending on the autonomy of the individuals treating cattle.  
Regardless of how extensive a protocol is, it is important that all of the people who will be using 
it have ownership in developing the contents, monitoring results, and updating the protocol.  In 
addition to benefits to the production facility, detailed protocols and records of education and 
agreement related to the protocols are very important to the veterinarian in the case of a violative 
drug residue or regulatory inspection.         
 
Several basic inclusions are required to allow consistent application of treatments and evaluation 
of what happens after these treatments are administered.  
 
 Characterization of the disease challenge 
 Case definitions 
 Regimen design 
 Consistent application of treatment protocols 
 Outcome evaluation 
 
What should be included in a complete dairy protocol? 
 
Mastitis 
 Environmental 
 Contagious 
Lameness 
 Footrot 
 Hairy heel wart 
 Sole ulcers/whiteline 
Respiratory disease 
 Adult cow 
 Neonatal 
 Heifers 
Metabolic disease 
 Ketosis 
 Hypocalcemia 
 Fatty liver 
 DA 
Metritis 
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Neonatal 
Pneumonia  
Enteric disease 
 
 
For comparison, what should you expect to be covered in a feedlot protocol? 
 
 Respiratory disease 
o Low risk (expected morbidity ≤ 10%, case fatality 1-2%) 
o High risk (expected morbidity > 10%, case fatality > 2% up to 10%) 
o Heavy cattle within 30 days of harvest (withdrawal times are now a primary 
consideration) 
o Acute interstitial pneumonia (AIP) 
o Tracheal edema (Honkers) 
o Diphtheria (relatively rare in the feedlot) 
 Gastrointestinal disease 
o Acidosis 
o Bloat 
o Coccidiosis 
 Musculoskeletal disease 
o Footrot 
o Toe and sole abscesses 
o Undifferentiated lameness (e.g., sprains) 
o Hairy heel wart (Strawberry footrot) 
 Central nervous system disease 
o Polioencephalomalacia 
o Thrombolic meningoencephalitis 
o Listeriosis 
 Miscellaneous 
o Rectal, vaginal, and uterine prolapses 
o Calvers and abortions 
o Anaphylactic shock 
o Bullers 
o Pinkeye 
o Abscesses 
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Required inclusions in a treatment protocol  
 
Characterization of the disease– Why is the animal sick?  This requires an investment in 
diagnostic tests and post-mortem exams.  The clients will start with the case definition, but your 
job is to be determining why these cases are occurring and working to minimize the need to use 
the protocol. 
 
Case definition – The description of an animal that meets your requirements for receiving 
treatment or for treatment success/failure.  
 
Regimen – Consists of the drug, dose, route, duration, frequency, and slaughter withdrawal. The 
regimen should be complete to the detail of needle size and injection or administration site. 
 
Case definition examples:  These bovine respiratory disease examples need to be characterized 
as important or misleading criteria.  Any disease has similar challenges. 
 
 Depression (see the example scoring system below) 
 Nasal discharge 
 Ocular discharge 
 Rumen fill/appetite 
 Rectal temperature 
 Auscultation? 
 
You may want to institute a scoring system to give some basic foundation to training new 
personnel and helping “adjust the dial” of current personnel or clients.  The scoring system 
below is simple yet allows discussion of just how depressed (and by inference, how advanced in 
disease) an animal is. 
 
 
Depression Score Clinical Signs 
0 Normal, no signs of depression 
1 Slower than pen mates but still perks up when 
approached and does not appear weak, actively 
follows your movements with a raised head 
2 Stands with head lowered, will perk up when approached 
but will return to depressed stance, moves slowly and falls 
towards back of group, may display signs of weakness such 
as incoordination  
3 Obviously very weak, difficulty in moving with 
group, raises head only when approached closely 
4 Moribund, unable to rise 
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Applying treatment guidelines 
 
It just isn't possible to accurately evaluate a practice or procedure that is not consistently applied.   
One source of inconsistency is applying different treatment regimens for bovine respiratory 
disease depending on initial rectal temperature or apparent severity of disease.  I haven’t found 
any data to support that these practices increase treatment efficacy.   
  
Should we routinely change (rotate) antimicrobials? 
 
There has been minimal publication on this subject concerning food animal therapeutic 
applications.  There are two core questions:  
 
 Does cycling have an impact on treatment efficacy?   
 Does cycling reduce resistance development? 
 
There is no data to suggest an affirmative answer to either question.  Another common question 
is “should we rotate drugs for second and third treatments”?  If you are finding adequate first 
treatment response in the majority of animals, the lack of efficacy noted in some animals at the 
end of the first treatment regimen is likely more closely associated with degree of disease 
advancement and time needed for response rather than interaction between the pathogen and the 
antimicrobial.  In these cases, it is probably not going to be a problem to continue therapy with 
the initial antimicrobial for animals not classified as first treatment successes. 
 
 
Example Treatment Guideline 
 
These treatment guidelines are an example of a feedlot protocol for respiratory disease in cattle.  
It is critical that the guidelines contain… 
 
 A case definition for initial case selection and success/failure determination 
 A detailed regimen description including drug, dose, route (needle description and 
volume/site if appropriate), duration, and frequency. 
 Any safety information for handling the drug that is different from other drugs. 
 A slaughter and/or milk withdrawal time 
 A case definition for success/failure and the disposition of animals for each outcome 
 
The guidelines should be routinely reviewed with the client and/or their employees.  The secret 
to a consistently applied protocol is the crew having ownership in the contents.  It is absolutely 
imperative that all agree to communicate prior to changing any aspect of the protocol. 
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Respiratory Disease 
 
Case definition - The animal is usually depressed (moves slowly, hanging head, drooping ears, 
“knuckling” of hind fetlocks) and may also have: 
 
nasal or eye discharge - Clear nasal discharge does not necessarily indicate respiratory disease, 
and may be normal early in the morning or during dry/dusty conditions.   
 
sunken flanks -  Decreased rumen fill indicates decreased feed intake.  This may be used as 
supportive evidence that the animal has respiratory disease, but really indicates that the animal 
needs to be examined for why it is not eating.  A full rumen should not keep you from examining 
an animal with other signs of disease; sick animals eat too. 
 
diarrhea (scours) - Diarrhea may accompany respiratory disease.  However, also evaluate the 
animal for other digestive disorders such as acidosis.   
 
 
Low Risk Cattle - Yearling cattle and low-stress calves where we expect to treat less than 10% 
for respiratory disease and expect less than 0.5% to die from respiratory disease. 
 
Low Risk Treatment #1 - Slaughter withdrawal 28 days 
 
Day 0  3-day miraclemycin - 4.5 mL/100 lbs. subcutaneously in the neck,  
16   gauge, ¾” needle, maximum of 10 mL/site. 
  
 Day 1 (24 hours)  Observe only 
  
Day 2 (48 hours)  Observe: Animals which have shown no response  
may be moved to treatment #2 ahead of schedule, but this 
should be < 5% of the cattle.  Low risk status should be 
reconsidered if ≥ 5% of the cattle have not responded by 
this time.   
 
 Day 3 (72 hours)  Make your final decision on this day.  Two options: 
     discontinue treatment (the animal has recovered), or 
     advance to treatment #2.   
 
Case definition for success/failure determination -  Cattle classified as treatment successes are 
displaying no or only minimal clinical signs as described in the initial case definition. 
Determining rectal temperature is not necessary if the animal appears  
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clinically normal.  Cattle classified as failures, and moved to the next treatment, are  those 
displaying visible depression or respiratory disease symptoms.  These cattle will be moved to 
treatment #2.  
 
Continue the guidelines with the next treatment option and other disease protocols.  
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Avoiding Carcass Residues 
Mike Apley, DVM, PhD, DACVCP 
Department of Veterinary Clinical Sciences, Kansas State University 
 
 
 
Introduction 
 
Dairy cattle end their careers in the beef industry, and what happens towards the end of their 
dairy career has a huge impact on the reputation and safety of the beef industry.   Two main 
components of carcass quality are drug residues and injection site lesions.  There are high risk 
behaviors which contribute to problems in each of these areas.   
 
 
Avoiding Violative Carcass Residues 
 
In the U.S., it’s simple to avoid violative carcass residues, just use the product exactly as labeled 
and observe the withdrawal time. The label regimen includes disease indication, dose, route, 
duration, frequency, and injection site.  A mechanism for checking withdrawal times prior to 
shipping of cull cows should be instituted just as for returning cows to the milking string after a 
milk withdrawal time.  A system where the cow does not ship until her withdrawal time has been 
checked is a basic tenant of residue avoidance programs.   
 
If the product is to be used in any manner inconsistent with the label, then a veterinarian must 
prescribe this use within a veterinarian-client-patient relationship and the regulations of the 
Animal Medicinal Drug Use Clarification Act (AMDUCA) must be followed.  The veterinarian 
is responsible for determining an exaggerated slaughter and milk withdrawal time; the Food 
Animal Residue Avoidance Databank (FARAD) is the best source for assigning extended 
withdrawal times.  If FARAD can’t provide a withdrawal time, it is a good indication that 
sufficient data do not exist to assign a withdrawal time for this extralabel use, and the drug 
should not be used for this purpose. 
 
Foreign markets lead to some challenges in that we have different maximum residue limits 
(MRLs) in different markets.  Their withdrawal times may be based on different formulations 
(you need to check), and different calculation procedures, so without the appropriate information 
we can get in trouble by just adapting foreign withdrawal times.  If you are selling into a system 
where a food animal product will be sold into a foreign market, you must work with the 
purchaser to assure that the proper withdrawal times are observed. 
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Four Basic Tenants of Residue Avoidance 
 
Here are 4 concepts which I feel are very important in avoiding violative residues. 
 
1. Serum/plasma doesn’t necessarily represent tissue concentrations.  And, elimination 
characteristics in serum/plasma are not necessarily the same as the tissues, which may differ 
dramatically amongst themselves.  Sometimes veterinarians have relied on serum or plasma 
drug elimination estimates to approximate extended withdrawal times for extralabel use.  
Besides the potential difference between the blood and target residue tissues, the science 
behind residue depletion can be complex, so back to FARAD. 
   
2. Drug elimination from edible tissues can behave very differently beyond and below existing 
data (i.e., you can’t extrapolate beyond the available residue depletion data to predict 
behavior at lower concentrations, it might be the same or it might not).  One of the reasons 
you might not be able to safely use a product is because it has no tolerance and there are no 
data to show when the drug reaches an undetectable concentration using current technology.   
 
3. If a foreign market is a possibility, get help. 
 
4. Zero is getting smaller and smaller.  Technologies such as advanced mass spectrometry 
systems are making it possible to detect lower and lower concentrations of residues.  If there 
is no tolerance for an extralabel drug, then any detected in meat, milk, or eggs is volative. 
 
 
Development of Tolerances in the United States 
 
To understand how violative residues can happen, it is important to understand the science that 
goes into establishing how much of a drug or metabolites can remain in a tissue at slaughter, and 
how withdrawal times are established to assure that this concentration is not exceeded.  The 
progression of arriving at a withdrawal time is NOEL, ADI, safe concentration, tolerance, and 
finally a withdrawal time.   
 
First, toxicity studies are used to determine a No Observable Effect Level (NOEL). A safety 
factor is then applied to the NOEL based on the type of toxicity studies used in developing the 
NOEL, which creates an Acceptable Daily Intake (ADI, in µg /kg).  The ADI is less than the 
NOEL. This ADI is for total residues of the drug. The ADI is taken times a 60 kg human to come 
up with the total ADI (total µg which may be consumed in a day). 
  
This total ADI is then divided by the grams of intake for each of the edible tissues to come up 
with the safe concentration for total residues of the drug in each tissue. The total estimated daily 
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intake for each of the potential target residue tissues is used for each of the tissues in this 
calculation:  muscle 300 g, liver 100 g, fat 50 g, and kidney 50 g.  If the drug is labeled for 
lactating dairy cattle, the ADI is split between each of these tissues and milk. If the drug does not 
have this approval, then no ADI is partitioned to milk, and the total ADI is used to determine the 
safe concentration for each of the 4 tissues. Generally half of the ADI is allocated to the tissues 
and half to the milk. The same goes for laying chickens; the ADI is partitioned between the 
chicken tissues and eggs. For an explanation of the calculations, see pages 15 and 16 of guidance 
# 3 from the FDA Center for Veterinary Medicine (FDA/CVM GFI #3)  
 
The Code of Federal Regulations (CFR) for tolerances is a historical document reflecting the 
procedures in place at the time of the establishment of that tolerance (21 CFR Part 556).  For 
example, many of these tolerances were established with a muscle consumption value of 500 g, 
resulting in a lower safe concentration than would be established with the current value of 300 g. 
The sponsor may ask the CVM to recalculate the safe concentrations and tolerances for the 
tissues based on the new consumption value and the existing ADI. For example, liver 
consumption is now 100 g rather than 250 g (food factor of 0.5 x 500g for meat, is the way they 
used to figure it). 
 
If the safe concentration is left as total residues, you have a maximum residue limit (e.g., 
European Union), where the regulatory method specifies the parent drug and metabolites to be 
measured (e.g., chlortetracycline and 4-epichlortetracycline). In the U.S., we focus on the marker 
residue, which is either the parent drug or a key metabolite. This is done by determining the % of 
the total residues represented by the marker residue at or near the withdrawal time.  For example, 
if the marker residue comprises 40% of the total residues, then the tolerance for this marker 
residue is 40% of the total safe concentration for all residues. With that understood, it is now 
clear that a MRL of 100 ppb would be more stringent that a tolerance of 100 ppb. The tolerance 
is for one specific compound, which may be the parent compound or a dominant metabolite. The 
MRL would include this compound and whatever additional metabolites (or perhaps the parent) 
are included in the regulatory method.   
    
In the U.S., the tolerance for a carcinogen is zero, and the withdrawal time is based on a non-
carcinogenic metabolite being at a concentration which indicates that the carcinogenic parent 
drug (and perhaps carcinogenic metabolites) is not detectable. If the work were done again today 
for these compounds, the withdrawal time would have to be extended for some due to the ever 
decreasing criteria of “non detectable”.   
   
How do zero tolerances happen?  If there are no established tolerances or MRLs, then any 
amount detected is violative. Of course the MRL can be set at zero, too, such as in the case of 
carbadox (swine feed medication) in muscle for Japan, Hong Kong, Korea, and about 
everywhere else. In the U.S., the tolerance for the marker residue is 0.03 in the liver, indicating 
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that no carcinogenic compounds could be detected in edible tissues when the marker residue is at 
this concentration. 
 
Recent Big Changes for Residue Testing and Criteria in Cull Dairy Cows 
 
The Food Safety Inspection Service (FSIS) has determined that since no tolerance is listed for 
dexamethasone for any animal species in 21 CFR part 556, that the tolerance is therefore zero 
and any amount detected will be violative.  This is in spite of there being no required withdrawal 
time on the label for dexamethasone, which is labeled for applications in cattle, including 
ketosis.  Therefore, a withdrawal time is now necessary to attempt to achieve a residue 
concentration below the applicability level of the new FSIS mass spectrometry testing method, 
which is 50 ppb (FSIS 9 CFR parts 417).  This interpretation of the tolerance for dexamethasone 
affects all food animal species.  The best source for new, extended withdrawal times is FARAD  
which will base the recommendation off of the dose, route, duration, and frequency of 
administration being used.   
 
Another big change for residues in cull dairy cows is the FSIS and FDA interpretation that 
tolerances established in cattle do not apply to dairy cattle unless dairy cattle are specifically 
included on the label.  For example, if florfenicol (Nuflor, Merck Animal Health) is used for the 
label indication of bovine respiratory disease in beef cattle (excluding veal calves) or dairy cattle 
(females, under 20 months of age), the label withdrawal time is 38 days for the 40 mg/kg 
subcutaneous dosing regimen (Florfenicol label, Animal Drugs @ FDA).   The tolerance for 
cattle which is the basis for this withdrawal time is 3700 ppb of florfenicol amine (the marker 
residue) in the liver, which is the target residue organ (21 CFR Sec. 556.283). 
 
With the current interpretation, if used in a dairy female bovine aged 20 months of age or older 
(the same as the lactating cow definition of the FDA/CVM), then the tolerance becomes zero.  
Any concentration above the FSIS mass spectrometry applicability level of 100 ppb would be 
violative.   This is 37 times less than the tolerance established for beef cattle.  The veterinarian 
involved in the decision for any extralabel use of florfenicol in lactating dairy cows should 
consult with FARAD to determine a substantially extended withdrawal time.  
 
This change is only for drugs without lactating dairy cattle on the label.   Antibiotics such as 
ceftiofur (Naxcel, Excenel, Excede, Pfizer Animal Health) and Liquamycin LA-200 (Pfizer 
Animal Health), which have lactating dairy cattle on the label, will have any residues evaluated 
according to the tolerance established for the drug by the FDA/CVM.  
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What Goes Wrong When Residues Occur? 
 
The top 10 residues in cull dairy cows, in order of occurrence, from 2005 to 2010 are (FDA 
compliance and Enforcement): 
 Penicillin 
 Flunixin (only cattle that are positive for antibiotics are tested for flunixin) 
 Sulfadimethoxine 
 Gentamicin 
 Ceftofur 
 Sulfamethazine 
 Oxytetracycline 
 Neomycin 
 Tilmicosin 
 Tetracycline          
 
Penicillin is an excellent example of a drug available over-the-counter for which the label is not 
commonly followed.  Alterations in dose, route, volume per injection site, and injection site are 
common, and require careful construction of an extended slaughter withdrawal time in 
conjunction with a veterinarian. 
 
Common causes of residues are (FDA compliance and enforcement): 
 Exceeding the approved dose 
 Shortening the withdrawal period 
 Using a drug in an extralabel manner without the required veterinary involvement 
 Using a drug in an unapproved species (e.g., lactating dairy cow) 
 Altering the site of administration from the label indication 
 Giving the wrong drug by mistake 
 
Other big deficiencies leading to the occurrence of violative residues are the lack of written 
treatment guidelines which serve as the basis for personnel training, and the lack of treatment 
records. 
 
How Quality Assurance Has Been Addressed 
 
The precursor to Beef Quality Assurance (BQA) began in the late 1970s as the Beef Safety 
Assurance program.  In the early 1980s, the Beef Safety Assurance program focused on making 
sure beef was free from chemical residues.  Beef Quality Assurance Programs funded by 
checkoff dollars began in individual states in the early 1990s, about the same time that the Beef 
Quality Task Force was started.  A real milestone that I remember is the first National Beef 
Quality Audit in 1991.  This was a real eye opener as to what our injection practices were 
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causing in carcasses in the packing plants.  These types of data drive real changes in the industry, 
such as our changes in injection practices for clostridial vaccines.   Repeated audits encouraged 
the industry to continue with education initiatives as key indicators improved over the next 
decade.   Today, the beef industry continues an emphasis on subcutaneous injections and the 
proper locations for all injections.   
 
The first National Market Cow and Bull Beef Quality Audit was conducted in 1994.  During the 
1990s, states with large populations of dairy cattle adapted BQA principles to implement dairy 
quality assurance programs which were also geared to producers.  A transportation BQA manual 
came out in 2006, followed by the national BQA trainers manual in 2008 and the initiation of the 
BQA awards program (for both beef and dairy) in 2009.  Also in 2009, the BQA Feedyard 
Assessment program began, and the National Dairy Animal Care & Quality Assurance Manual 
was released.  And most recently, in 2010, The BQA stocker/cow-calf, seedstock assessment 
manual was made available.    
 
The Beef Quality Assurance program started in the 1970s and has continued to expand across 
different production segments to address subjects such as residues, carcass quality, and animal 
handling.  This history and the documents may be accessed at the BQA site (Beef Quality 
Assurance).   The National Dairy Animal Care and Quality Assurance Producers Manual may be 
downloaded directly from this website (Dairy BQA manual).    This manual encompasses the 
National Beef Quality Assurance Guidelines issued by the National Beef Quality Assurance 
Program and the Principles & Guidelines set forth by the National Dairy Animal Well-Being 
Initiative. 
 
Between state and national initiatives, a lot of good people have worked hard to provide the basis 
for quality assurance in cull dairy cattle, including a big emphasis on violative residue avoidance. 
The lack of individual recognition of the multiple state efforts in beef and dairy quality assurance 
in this article by no means is intended to ignore these efforts.   
 
Putting It All Together In a Plan 
 
One of the programs specifically focused on residue avoidance in cull dairy cows is the 
Wisconsin Veterinary Medical Association and Professional Dairy Producers of Wisconsin 
Hazard Analysis and Critical Control Points (HAACP) plan (WVMAs HAACP Plan).  This plan 
started when Wisconsin was identified as leading the nation in dairy beef residues in 2009.  The 
plan focuses on 6 key points. 
 
 A veterinary-client-patient relationship 
 A drug list detailing all drugs used on the dairy and how they are used 
 Developing protocols based on the farm and skill sets of employees 
 74 
 
 Standard operating procedures (SOPs) 
 Records 
 Oversight by a veterinarian focused on drug use, protocol/SOP drift, identification of 
problem cows   
 
Perhaps one of the most compelling slides in the WVMA presentation on this HAACP plan 
states that true jeopardy is having protocols and not following them.  This HAACP plan does a 
nice job of summarizing the messages of many organizations working to assure carcass quality 
from dairy beef.  If you combine this plan with the common problems the FDA/CVM found in 
residue violation cases, the road map is obvious. 
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Antimicrobial Resistance in Human and Veterinary Patients 
Mike Apley, DVM, PhD, DACVCP 
Department of Veterinary Clinical Sciences, Kansas State University 
 
 
We can split this discussion into two parts, not necessarily unrelated.  The first is what resistance 
challenges we might see in infectious diseases of food animals that arise from our use in animal 
agriculture.  The second part is any effect we may have on human therapeutics.  
 
These proceedings discuss 
 The definition of resistance 
 Selection for resistance 
 Resistance challenges in human health 
 Resistance challenges in veterinary species 
 Transfer of resistance from animals to humans 
 Tetracyclines as an example in cattle 
 
To discuss the relevance of food animal antimicrobial use to human therapeutics, we first need to 
outline the resistance challenges in both human and veterinary medicine.  This presentation 
attempts to summarize some of the major concerns in resistance development along with key 
articles explaining relevance, epidemiology, and prevalence.  It is not intended to be an 
exhaustive review of the literature and the interested practitioner should use the cited literature 
herein as a basis for continued, extended reading.  But before we can discuss resistance, we must 
define resistance.   
 
What kind of resistance are we talking about? 
 
We sometimes become confused as to the type of “resistance” we are talking about.  As 
clinicians, you are concerned about clinical resistance, based on clinically derived breakpoints.  
These approved breakpoints are developed and approved by the Clinical and Laboratory 
Standards Institute Veterinary Antimicrobial Susceptibility Testing Subcommittee (CLSI VAST) 
based on the following. 
 Clinical outcomes coupled with pathogen susceptibility data 
 MIC distributions of wild type isolate collections 
 Pharmacokinetic/pharmacodynamic modeling 
 
These breakpoints are intended to give guidance on the probability of the antibiotic working on a 
combination of a pathogen, antimicrobial, disease, animal species, and specific treatment 
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regimen.  Once you deviate from any of these, the predictive value of the breakpoint is greatly 
diminished.   
 
The second type of “resistance” is related to changes in population profiles of “wild type” 
susceptibility distributions.  Instead of a clinical breakpoint, these are now referred to as an 
“epidemiological cutoff”.  These cutoffs are defined to indicate a change from the original 
population minimal inhibitory concentration (MIC) distribution, and may be developed to 
indicate appearance of resistance genes.  Regardless, they are not necessarily correlated to 
clinical response and it is very important to understand what changes based on epidemiological 
cutoffs convey in relation to clinical efficacy.  One of the outcomes of using both 
epidemiological cutoffs and clinical breakpoints is that different monitoring systems may be 
declaring “resistance” at different MICs.   
 
So where do resistant organisms come from? 
 
Here is the basic question.   
 Do resistant organisms develop from spontaneous mutations in your patient (or a 
population of patients, such as in some food animal applications) during antimicrobial 
use and then proliferate within the favorable climate of antimicrobial selection pressure?   
 Or, are they already present at a low prevalence level and then proliferate in the new 
environmental “rules” imposed by the presence of antimicrobials (clonal dissemination 
and selection)? 
 
My impression from the literature and sitting through and participating in meetings, debates, and 
outright arguments is that dissemination of resistant bacterial clones is a primary driver in what 
we are seeing in human and veterinary medicine.  Spontaneous mutations can and do occur, but 
the rapid changes in resistance over broad areas, and also the similarities between isolates 
suggests that the spread of clones is a primary driver.  Clones may be inaccurate in that it implies 
that it is the spread and proliferation of a single organism, when in fact what really matters is the 
spread and dissemination of genetic elements that code for resistance.   
 
Another very basic concept is that selection for a resistant pathogen or bacteria may be due to an 
entirely different selection pressure than the antimicrobial in which we happen to be interested.  
Multiple-drug resistance mechanisms allow co-selection for resistance traits.  And, it doesn’t 
even have to be an antimicrobial in the way we typically think of them.  Co-selection by 
environmental disinfectants can co-select for antimicrobial resistance, as demonstrated for pine 
oil for E. coli, and triclosan for Pseudomonas aeruginosa.1,2  The presence of pathogens such as 
Vancomycin-Resistant Enterococci (VRE), Pseudomonas,  and Methicillin-Resistant 
Staphylococcus aureus (MRSA) on surfaces, pagers, and stethoscopes has been well documented 
in human studies.    
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We don’t cause the original spontaneous mutations.  But, once these mutations take hold in an 
environment, we are responsible for aiding in selection and spread.  As Pogo said, “We have met 
the enemy and he is us”.  
 
What are the challenges on the human side of medicine? 
 
Hospital acquired infections.  One publication gives us a quick look into the challenges in 
human hospitals.  These data are from a Centers for Disease Control and Prevention (CDC) 
summary.3  The objective was to describe the frequency of selected antimicrobial resistance 
patterns among pathogens causing device-associated and procedure-associated healthcare-
associated infections (HAIs) reported by hospitals in the National Healthcare Safety Network 
(NHSN).  Data were collected on HAIs reported to the Patient Safety Component of the NHSN 
between January, 2006 and October, 2007.  These HAIs included… 
 Central line-associated bloodstream infections 
 Catheter-associated urinary tract infections 
 Ventilator-associated pneumonia 
 Surgical site infections 
 
Overall, 463 hospitals reported 1 or more HAIs: 412 (89%) were general acute care hospitals, 
and 309 (67%) had 200-1,000 beds. There were 28,502 HAIs reported among 25,384 patients.   
The 10 most common pathogens accounting for 84% of reported HAIs were… 
 
 Coagulase-negative staphylococci (15%) 
 Staphylococcus aureus ( 15%)  
 Enterococcus species (12%)  
 Candida species (11%)  
 Escherichia coli (10%)  
 Pseudomonas aeruginosa (8%)  
 Klebsiella pneumoniae (6%)  
 Enterobacter species (5%)  
 Acinetobacter baumannii  (3%)  
 Klebsiella oxytoca (2%) 
 
As many as 16% of all HAIs in this report were associated with the following multidrug-resistant 
pathogens. 
 
 Methicillin-resistant Staph. aureus (8% of HAIs),  
 Vancomycin-resistant Enterococcus faecium (4%), 
 Carbapenem-resistant Pseudomonas aeruginosa (2%),  
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 Extended-spectrum cephalosporin-resistant Klebsiella pneumoniae (1%), 
 Extended-spectrum cephalosporin-resistant E. coli (0.5%), 
 Carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli (0.5%).  
 
“Bad Bugs, No Drugs” report of the Infectious Disease Society of America  
 
In 2004, the Infectious Disease Society of America (IDSA) came out with their “Bad Bugs, No 
Drugs” report.4  This report was updated in 2009, implicating the same organisms as primary 
challenges for antibiotic resistance in human medicine.5  The primary pathogens were termed the 
“ESKAPE” pathogens because they escape attempts at antimicrobial therapy. 
 
Enterococcus faecium 
Staphylococcus aureus 
Klebsiella pneumoniae 
Acinetobacter baumanii 
Pseudomonas aeruginosa 
Enterobacter spp. 
 
In the 2009 report, these pathogens were still implicated as being responsible for the majority of 
U.S. hospital infections.  In addition, CDC data show rapidly increasing rates of infection due to 
Methicillin-Resistant Stapylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), 
and fluoroquinolone-resistant Pseudomonas aeruginosa.  The report stated that more people now 
die of MRSA infection in U.S. hospitals than HIV/AIDS and tuberculosis combined.  In addition, 
several very resistant Gram (-) pathogens are emerging as significant pathogens in the U.S. and 
around the world:  Acinetobacter species, multidrug-resistant Pseudomonas aeruginosa, 
carbapenem-resistant Klebsiella species and E. coli.  The carbapenems (e.g., imipenem and 
meropenem) are our most powerful beta-lactam antibiotics, and the appearance of widespread 
resistance to these antimicrobials is very alarming. 
 
Centers for Disease Control and Prevention Report – Antibiotic Resistance Threats in the 
United States, 2013 
 
The Centers for Disease Control and prevention recently released a report describing the major 
antibiotic resistance threats to human health.6  In this report, the major threats were classified as 
threat levels of urgent, serious, and concerning. 
 
Microorganisms with a threat level of urgent – These are high-consequence antibiotic-
resistant threats because of significant risks identified across several criteria. These 
threats may not be currently widespread but have the potential to become so and require 
urgent public health attention to identify infections and to limit transmission. 
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Clostridum difficile 
Carbapenem-resistant Enterobacteriaceae 
Drug-resistant Neisseria gonorrhoeae 
 
Microorganisms with a threat level of serious – These are significant antibiotic-
resistant threats.  For varying reasons (e.g., low or declining domestic incidence or 
reasonable availability of therapeutic agents), they are not considered urgent, but these 
threats will worsen and may become urgent without ongoing public health monitoring 
and prevention activities. 
 
Multidrug-resistant Acinetobacter 
Drug-resistant Campylobacter 
Fluconazole-resistant Candida 
Extended spectrum -lactamase producing Enterobacteriaceae (ESBLs) 
Vancomycin-resistant Enterococcus (VRE) 
Multidrug-resistant Pseudomonas aeruginosa 
Drug-resistant non-typhoidal Salmonella 
Drug-resistant Salmonella typhi 
Drug-resistant Shigella 
Methicillin-resistant Staphylococcus aureus (MRSA) 
Drug-resistant Streptococcus pneumoniae 
Drug-resistant tuberculosis 
 
 Microorganisms with a threat level of concerning – These are bacteria for which the 
threat of antibiotic resistance is low, and/or there are multiple therapeutic options for 
resistant infections.  These bacterial pathogens cause severe illness.  Threats in this 
category require monitoring and in some cases rapid incident or outbreak response.   
 
Vancomycin-resistant Staphylococcus aureus (VRSA) 
Erythromycin-resistant Group A Streptococcus 
Clindamycin-resistant Group B Streptococcus 
 
 
Resistance challenges in veterinary medicine (including zoonotic concerns): 
 
Weese has published an excellent review of antimicrobial resistance issues in companion animals 
(2008).7   The primary organisms addressed in this review are as follows. 
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 Staphylococcus aureus and Staphylococcus pseudintermedius:  both methicillin 
susceptible and resistant. 
 Enterococci:  Enterocococcus faecium and Entercoccus faecalis. 
 Streptococci:  Strep. zooepidemicus and Strep. Equi in horses, Strep. canis 
 Escherichia coli 
 Salmonella 
 Pseudomonas 
 
The issue of MRSA highlights issues of zoonotic interactions from multiple veterinary species. 
 
Methicillin-Resistant Staph aureus (MRSA):  a 2008 review article has summarized literature 
on animal occurrence, including cattle, dogs, cats, sheep, chickens, horses, rabbits, seals, and 
psittacine birds.8  Significant research has been conducted evaluating the potential for exchange 
of isolates between people and their pets.  
 
Kottler, et al., evaluated the prevalence of MRSA in people and pets in the same household.9  
The sample consisted of one human nasal swab and one dog or cat nasal and fecal swab from 
586 households.  Staph aureus was classified as methicillin resistant (MRSA) or susceptible 
(MSSA).  Pulsed-field gel electrophoresis (PFGE) and spa-typing were used to characterize the 
relatedness of S. aureus and MRSA between pets and humans.   There was no difference in 
MRSA prevalence in households with human healthcare workers, veterinary healthcare workers, 
or without healthcare workers.  The following table displaying prevalence of MSSA and MRSA 
in humans and pets is adapted from the publication.   
 
MSSA MRSA 
Humans 21.5% 5.6% 
Pets 7.9% 3.4% 
 
In 4 of the 586 households (0.7%), the MRSA found in humans was the same strain as that found 
in the pet. 
 
Faires, et al., evaluated the prevalence of concurrent infection in households where either a 
person or pet had a diagnosed MRSA colonization.10  In part 1 of the study, 22 households were 
identified as having an MRSA infection in a pet (19 dogs and 3 cats).  In these households, 10 of 
56 humans (17.9%) were also colonized with MRSA.  In part 2 of the study, 8 households were 
identified where humans had MRSA cultures from dermal abscesses.  In only 1of these 
households was MRSA also isolated from a pet.  In almost all cases of co-colonization or 
infection, the isolates were indistinguishable by PFGE. 
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O’Mahony, et al., evaluated MRSA isolates from dogs, horses, a cat, a rabbit, and a seal in 
Ireland along with isolates from 10 caregivers.11   The PFGE results for the equine MRSA 
isolates were indistinguishable from the results for those isolates originating from the caregivers 
for the horses.  
 
Several studies have evaluated risk factors for infection with MRSA in companion animals.   
Faires, et al., evaluated risk factors for 40 MRSA infected dogs compared with 80 MSSA 
infected dogs. 12 The highest prevalence of both infections was in ears and skin.  The statistically 
significant risk factors for MRSA infection as compared to MSSA infection included the use of 
any antimicrobial prior to diagnosis (odds ratio 2.84), use of fluoroquinolones (OR 3.58), use of 
β-lactams (OR 3.58), or intravenous catheterization (OR 3.72).  
 
A retrospective study in horses in Canadian and American referral hospitals evaluated MRSA 
infections in 115 horses.13  The infections originated both in the referral hospitals and in the 
community, with the frequency of both being approximately equal.  Community acquired 
infections were significantly associated with previous hospitalization and previous gentamicin 
therapy.  Hospital-acquired MRSA infections were significantly associated with infected incision 
sites.    
 
Increasing attention in the literature has been paid to MRSA in swine and potential zoonotic 
concerns. There is extensive literature on types and occurrence of MRSA in farm workers.  
While swine workers and veterinarians have been demonstrated to have nasal carriage of the 
MRSA type found in swine herds, epidemiological studies suggest that colonization is primarily 
limited to those working with the swine and further transmission is limited to familial 
communities of these exposed workers.14  In the U.S., the human community-acquired outbreak 
strains are different from animal strains.  In the Netherlands, a new type of MRSA (ST 398) is 
epidemiologically associated with pig and cattle farmers and is said to be > 20% of carriage in 
humans.15  MRSA has also been identified in bovine mastitis isolates.16  The authors of a 2012 
study using single nucleotide polymorphisms (SNPs) to evaluate 89 CC398 MRSA isolates 
proposed that this MRSA originated in humans as a methicillin-susceptible isolate and then 
acquired tetracycline and methicillin resistance in livestock, but also lost phage-carried human 
virulence genes.17 MRSA CC398 has been documented to cause disease in humans, although it is 
not a major player in MRSA-associated disease in humans and appears to be a poor long-term 
colonizer.18,19   
 
MRSA is an example of a resistant organism (which may also be multi-drug resistant) that brings 
the issue of treating our veterinary patients together with concerns about the effect of this 
pathogen’s presence on our clients.  There are no free lunches, as pathogens which have 
developed resistance to one main line of therapy will likely also develop resistance to the next 
great thing in therapy.   
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Bovine respiratory disease pathogens:  Another area of resistance concern involves the 
pathogens for bovine respiratory disease as displayed in isolates originating from high-risk 
calves in the United States.  Lubbers and Hanzlicek published a retrospective analysis of 
Mannheimia haemolytica susceptibility results during 2009-2011 from the Kansas State 
Diagnostic Laboratory.20 The percentage of isolates showing resistance to at least 3 of our main 
classes of antibiotics used for BRD were 42%, 46%, and 63% in 2009, 2010, and 2011 
respectively.   
 
Has the transfer of resistance from food animals to humans been demonstrated? 
 
The Pew Trust recently funded a paper which summarized evidence for a link between food 
animal use of antimicrobials and therapeutic resistance in humans.21  This paper, by Marshall and 
Levy, evaluated evidence for animal to human spread of antibiotic resistance.  Ten references 
were cited which detailed some type of similarity between an isolate of a bacteria in food 
animals (5 papers for human colonization and 5 for infection) which were related to direct or 
indirect animal contact.  Only one of these papers documented adverse effects in the humans, 
that being a Salmonella Newport hamburger-borne outbreak.  These are basically what there is 
out there.   
 
In my opinion, it is clearly shown that bacteria can be exchanged between animals and humans, 
either directly or through food, and that theses pathogens may be resistant.  The challenge 
relating to interpreting the effect and importance of these relationships is shown by the fact that 
few of the isolates shown in these references are included on the “ESKAPE” list.    
Some notable quotes from this article include the following. 
 
“In the above examples, the link to nontherapeutic antibiotic use in the farm animals is still 
circumstantial and largely implied, often because the authors do not report any statistics on 
farm use of antibiotics.  Interpreting these studies is also difficult because of the widespread 
resistance to some drugs in bacteria of both animals and humans and the ubiquitous nature of 
resistance genes.  Moreover, the same farmer may use antibiotics for both therapeutic and 
nontherapeutic purposes.”  
 
“The complexities of the modern food chain make it challenging to perform controlled studies 
that provide unequivocal evidence for a direct link between antibiotic use in animals and the 
emergence of antibiotic resistance in food-borne bacteria associated with human disease.”  
“While this concrete evidence is limited, a small number of studies have been able to link 
antibiotic-resistant infection in people with bacteria from antibiotic-treated animals. While not 
necessarily involving NTAs, these studies substantiate the considerable ease with which bacteria 
in animals move to people.”  
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We can agree on these passages.  It certainly is hard to link the findings in these 10 references to 
specific drug uses.  I especially agree that sorting out the uses for increases in rate of gain and 
feed efficiency is not based on any type of evidence.   
 
“For example, a multidrugresistant Salmonella enterica strain in a 12-year-old Nebraska boy 
was traced to his father’s calves, which had recently been treated for diarrhea. Isolates from the 
child and one of the cows were determined to be the same strain of CMY-2-mediated 
ceftriaxone-resistant S. enterica.”  
 
“It is now believed that the 1992 multiresistant Vibrio cholerae epidemic in Latin America was 
linked to the acquisition of antibiotic-resistant bacteria arising from heavy antibiotic use in the 
shrimp industry of Ecuador (13, 156).”  
 
My confidence in the authors being straight up about interpretation of the articles is shaken by 
the interpretation of the Salmonella article.  In this reference, the authors of the original paper 
(Fey, et al.) didn’t do what I did; they didn’t actually visit the farms or interview any of the 
involved people.22   The facts are that only one, 1 gram vial of Naxcel was dispensed for 
treatment of the calves in the 4 affected herds, and that was only for the index case prior to 
culture and susceptibility results becoming available.  How do Marshall and Levy know that the 
calves were treated, or that treatment contributed to the resistance of the Salmonella?  They 
don’t, but is doesn’t stop them and many others from the insinuation that antibiotic use in food 
animals caused this resistant organism to be present.  In fact, if the original authors would have 
done their field work, they would have found that geese were very prevalent on the calving 
grounds (a major flyway), that the isolate suddenly appeared in close temporal association in all 
herds, and that the isolate was gone the next year and not seen since.  All of these point to a 
transient presence, most likely introduced by migratory water fowl.  This organism was unable to 
find a niche due to antimicrobial use or any other factor.  So, an article documenting the 
transmission of an enteric pathogen from a food animal population in which it was transiently 
present is now used as an indictment of antimicrobial use in animals.   
 
The sum of evidence and the nature of the argument is best summed up by the following 
conclusion statement from the Marshall/Levy article. 
 
“Data gaps continue to fuel the debate over the use of NTAs in food animals, particularly 
regarding the contribution and quantitation of commensal reservoirs of resistance to resistance 
in human disease. Nonetheless, it has been argued reasonably that such deficits in surveillance or 
indisputable demonstrations of animal-human linkage should not hinder the  
implementation of a ban on the use of nontherapeutic antibiotics.”  
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That is the essence of the argument.  The cited reasonable argument is a letter to the editor.  I am 
certainly not arguing that there is not a link between food animal bacteria and foodborne 
pathogens.  Nor do I argue that there is no evidence to show that resistant organisms can travel 
through the food chain, or be directly transmitted to humans.  However, we are establishing a 
level of evidence for evaluation of all uses of antimicrobials in food animals, not just growth 
promotant uses and the arguable classification of “nontherapeutic”, and this level of evidence for 
singling out individual use classes is troublesome.   
Tetracyclines as an example in cattle 
 
There are extensive, transmissible resistance genetic elements out there for the tetracyclines.  A 
2010 review of the tetracycline resistome noted 1,189 different reported resistance genes present 
in 84 bacterial genera, which included 354 bacterial species.23  These genes comprise 41 classes, 
with three major mechanisms. 
 
 Actively pumping the drug out of the cell 
 Enzymatic degradation of the drug 
 Protection of the drug binding site  
 
Another paper has documented the methods by which these genes are transferred between 
bacteria.24 
 
 Gram-negative and Gram-positive genes coding for tetracycline efflux are 
generally associated with plasmids. 
 tet(S) and tet(O) encode for ribosomal protection and are located both in the 
chromosome and in conjugative plasmids 
 tet(M) and tet(Q) (also ribosomal protection) are typically associated with 
conjugative transposons  
 Other mechanisms include enzymatic inactiviation (tet(X) and tet(37) 
 Mosaic genes have also been described, which are combinations of individual 
genes (e.g., tet(O/32/O)  
 
From these inputs, it is apparent that there are multiple options for tetracycline class resistance 
and that the mobility of these genetic options are well documented.   
 
The next point for consideration is the breadth of regimens and the use classifications across 
these regimens.  Here is the range of in-feed approvals for tetracyclines in cattle, with the highest 
dosing regimens at the top.  These are spaced to illustrate the range of doses.  (CTC = 
chlortetracycline, OTC = oxytetracycline, TC = tetracycline) 
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CTC:  10 mg/lb BW for up to 5 days 
CTC:  400 g/ton to provide 10 mg/lb per day in calves up to 250 lbs 
TC:  22 mg/kg for 3-5 days in calves 
 
 
OTC:  0.5 to 2.0 g/hd per day 
 
CTC:  350 mg/hd per day in beef cattle under 700 lbs 
CTC:  0.5 mg/lb per day in beef cattle over 700 lbs 
CTC:  350 mg/hd per day in beef cattle 
CTC: 25-70 mg/hd per day in calves 250-400 lbs 
CTC:  70 mg/hd per day in growing cattle over 400 lbs 
CTC:  0.1 mg/hd per day in calves up to 250 lbs 
 
       Rate of gain/Feed efficiency 
 
       Prevention or control claims 
 
       Treatment claims 
 
From this illustration, it is apparent that focusing on the rate of gain/feed efficiency claims as the 
“subtherapeutic” bogeymen implies that somehow there is a line where selection for resistant 
organisms increases or decreases based on label claims.  Obviously, there is no science-based 
information to drive this assumption, but rather, in my opinion, it is based on selecting the most 
politically acceptable route for an initial removal of food animal antimicrobial uses.  The 
challenge in allowing the rate of gain/feed efficiency antimicrobials to be removed based on the 
“precautionary principle” is that we then end up with this precedent in evaluating the 
prevention/control claims. 
 
How can we put the dose ranges above in some kind of context as to the potential for selecting 
for tetracycline-resistant organisms?  First, we need to evaluate what kind of dose it takes to alter 
the intestinal flora and/or select for resistant organisms in the gut.  But, even before that, just 
how much tetracycline remains active in the gut anyway?  My analysis of 7 published studies 
(rats, mice, humans, pigs) found a range of 0.2% to 13.4%, with an additional outlier showing 
67% in rats.   
 
These data were derived from experiments where they determined the actual active amount still 
functioning in gut contents or feces.  Some difficulty is brought into this because we don’t know 
exactly how this varies between different areas of the gut, and the resulting effects in various 
areas of the gut.  So right away it is apparent that the low doses have even less drug surviving to 
have an effect in the gut. 
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The next step is to determine just how much drug needs to be present, and active, in the gut to 
have an effect on the flora.  Several studies have evaluated this level.   
Carmen, et al. (2006) evaluated three concentrations of tetracycline in a chemostat system 
inoculated with human fecal flora.  Concentrations of 0.15, 1.5, and 15 µg/ml were used in the 
systems, equivalent to daily doses of 0.025, 0.25, and 2.5 mg/kg per day in a 60 kg human (based 
on fecal concentration data by van Marwyck, 1958).  Statistical analysis identified the lowest and 
middle concentrations as having no observable adverse effect on the bacterial population. 
 
Perrin-Guyomard, et al. (2001) used a human-flora-associated (HFA) mouse model to evaluate 
water tetracycline concentrations of 0, 1, 10, and 100 mg/liter administered for 8 weeks.25  Upon 
further calculation, these are equivalent to doses of 0, 0.125, 1.25, and 12.5 mg/kg BW.  The 
authors cited the highest dose as being capable of disrupting the capability to resist Salmonella 
infection by a resistant isolate.  At the lowest dose, there were transient increases in percent 
resistant Bacteroides fragilis and Enterococci.  These effects were more pronounced at higher 
doses. 
 
Tancrede and Baraket (1987) administered 2, 20, or 2000 mg/day to human volunteers for 7 
days.  In 60 kg humans, this would be equivalent to 0.03, 0.33, 33 mg/kg per day.26  The low 
dose caused no change in % resistance in the dominant anaerobes.  The two high doses did 
induce changes in resistance. 
 
The gastrointestinal tract characteristics of the human and human flora associated mouse are 
obviously quite different from the bovine, but as our only means of evaluating this effect, we see 
a pattern in these 3 studies of daily doses of 0.25 and 0.03 mg/kg per day having no effect in two 
of the studies.  In the other study, a dose of 1.25 mg/kg caused no change in the ability for 
resistant Salmonella to colonize the gut, while the low dose of 0.125 mg/kg per day caused some 
transient increases in resistant flora.  These mixed results highlight the uncertainty in this type of 
modeling, but do support a conclusion that effects are dose dependant, and that the lowest doses 
cause the least effect. 
 
Now let’s look at the dose ranges of tetracycline shown above and evaluate them in the light of 
calculated mg/kg per day.  
 
  
 88 
 
 
CTC:  10 mg/lb BW for up to 5 days   (22 mg/kg)                        
CTC:  400 g/ton to provide 10 mg/lb per day in calves up to 250 lbs (22 mg/kg) 
TC:  22 mg/kg for 3-5 days in calves (22 mg/kg) 
 
 
OTC:  0.5 to 2.0 g/hd per day (5.5 mg/kg for 500#) 
 
CTC:  350 mg/hd per day in beef cattle under 700 lbs (1.9 mg/kg for 800#) 
CTC:  0.5 mg/lb per day in beef cattle over 700 lbs (1.1 mg/kg) 
CTC:  350 mg/hd per day in beef cattle (1.1 mg/kg for 700#) 
CTC: 25-70 mg/hd per day in calves 250-400 lbs (0.62 mg/kg for 250#) 
CTC:  70 mg/hd per day in growing cattle over 400 lbs (0.22 mg/kg for 700#) 
CTC:  0.1 mg/hd per day in calves up to 250 lbs (0.002 mg/kg for 100#) 
 
       Rate of gain/Feed efficiency 
 
       Prevention or control claims 
 
       Treatment claims 
 
Even with all the uncertainties of model application, it is apparent that singling out growth 
promotion claims as the most likely candidate for removal does not focus on the most likely 
culprits for changes in gut flora resistance.  The growth promotion claims may have an effect, 
but we will have to address effects of the prevention/control claims sooner or later, and the 
precedents set for the growth promotion claims will follow us through to the others. 
 
What actually happens when tetracyclines are put in the feed of cattle? 
 
The effect of chlortetracycline addition to feed at 22 mg/kg per day has been shown to be 
transient when evaluated in light of resistance profiles of E. coli.27  In another study, including 
chlortetracycline in the feed for extended periods at a daily dose of approximately 0.03 mg/kg 
per day during a backgrounding and feeding phase in feedlot cattle increased the % of E. coli in 
the feces that were resistant to tetracyclines.28   A third study found that administration of 
chlortetracycline at 350 mg/head per day for 197 days caused a decrease in E. coli diversity and 
“…an increased linked inheritance of ampicillin and tetracycline resistance genes and prevalence 
of specific strains at day 197.”29 
 
These studies demonstrate measurable effects of regimens that may or may not reflect actual use 
durations or doses in practice.  However, the overall conclusion is yes, we can cause enteric flora 
changes with the tetracyclines in cattle. 
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Summary: 
 
This presentation just scratches the surface of the literature as to the resistance challenges in 
human and animal health, and the interaction within the two.  In my opinion, the major questions 
related to the use of antimicrobials in food animals are in relation to Campylobacter, Salmonella, 
and E. coli.  The issue of MRSA is currently one of colonization with a more minor contribution 
to human disease from zoonotic sources, but this relationship bears watching in the future.  
However, it is obvious that food animal uses have little if any direct contribution to a large 
portion of the most critical human antimicrobial resistance issues.    
 
In several parts of the world, the verdict has been returned on growth promotant uses of 
medically important (for human therapy) antimicrobials as evidenced by removal, or pending 
removal of these applications.  Our next challenge will be to balance risk and benefit of 
antimicrobial uses for prevention and control of disease in food animals.   
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Evolving Drug Use Regulations in Food Animals  
Michael Apley DVM, PhD, DACVCP 
Department of Veterinary Clinical Sciences, Kansas State University 
  
The pace of change in antimicrobial regulations for food animals continues to accelerate. There 
are 6 key areas with potential for extremely rapid change in the next 5 years. These areas are (1) 
the withdrawal of growth promotion uses of antimicrobials, (2) expansion of antimicrobial use 
reporting requirements, (3) continued legislative initiatives to remove antimicrobial uses for 
prevention or control of disease in food animals, (4) FSIS residue testing activities, (5) use of the 
AMDUCA regulations as a regulatory tool to attempt to decrease use of targeted drug classes in 
food animals, and (6) the potential for an FDA/CVM hearing on the hazard status of the use of 
tetracyclines and penicillins in animal feed. 
   
Key Area 1: Guidance 209, Guidance 213, and Veterinary Feed Directive 
Proposed Rule 
 
Links to the 3 documents discussed herein are available on the FDA Center for Veterinary 
Medicine website at http://www.fda.gov/AnimalVeterinary/NewsEvents/ CVMUpdates/ 
ucm378166.htm 
 
Guidance 209 – April, 2013 (Final Document) 
 
This guidance document puts forth two principles for which the FDA Center for Veterinary 
Medicine will seek voluntary compliance. 
 
Principle 1: The use of medically important antimicrobial drugs in food-producing animals 
should be limited to those uses that are considered necessary for assuring animal health. This 
means that any antimicrobial drug listed as medically important for human therapeutics in 
Appendix A of Guidance 152 will no longer be legal to be used for improvement in feed 
efficiency or rate of gain after implementation of this guidance. Guidance 209 specifically 
applies to antimicrobials used in the feed or water for food animals. The FDA states that they 
feel this principle applies to all antimicrobials used in food animals; however, Guidance 209 
does not address over-the-counter injectable antimicrobials such as procaine penicillin G and 
long-acting 200 mg/ml oxytetracycline products (e.g., Liquamycin LA-200®). 
 
Principle 2: The use of medically important antimicrobial drugs in food-producing animals 
should be limited to those uses that include veterinary oversight or consultation. This means that 
the remaining uses of medically important antimicrobials in the feed and water of food animals 
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(prevention, control, and therapy) will require authorization by a veterinarian through a 
veterinary feed directive. Additives for milk replacer are approved as feed additives, so they are 
included in this requirement. 
 
This list of medically important antimicrobials in Appendix A of Guidance for Industry #152 
includes these antimicrobial groups with current feed or water use labels (with examples of in- 
feed or in-water approved antimicrobials). The groups listed may have other drugs that are used 
in humans, but the examples listed are those used in food animals. These groups will be affected 
by Guidance documents 209 and 213. 
 Aminoglycosides: gentamicin, neomycin 
 Lincosamides: lincomycin 
 Macrolides: tylosin, tilmicosin (Pulmotil® currently requires a VFD in swine and cattle) 
 Penicillins (natural):  penicillin G included in combination products 
 Streptogramins: virginiamycin 
 Sulfonamides: Includes both potentiated (e.g., trimethoprim/sulfa) and non-potentiated 
sulfonamides. There are no current feed or water potentiated sulfa approvals in the U.S. 
 Tetracyclines:  chlortetracycline, oxytetracycline, tetracycline 
 
The list of medically important antimicrobials does not include the following antimicrobials with 
food animal labels. They will not require a VFD or prescription in the future based on Guidance 
209, nor will they lose growth promotion claims on the label, unless added to the list of 
medically important antimicrobials in the future. 
 Ionophores:  monensin, lasalocid 
 Flavophospholipol: bambermycins (e.g., Flavomycin®, Gainpro®) 
 Bacitracin 
 Tiamulin 
 
The list of medically important antimicrobials in Guidance 152, Appendix A, includes these 
antimicrobial groups for which there are no current food animal feed or water use labels in the 
United States. Extralabel use in feed is prohibited in the United States. Extralabel use in water 
is allowed when in conformance with the Animal Medicinal Drug Use Clarification Act 
(AMDUCA) regulations. 
 Penicillins – Penase resistant, antipseudomonal, and aminopenicillin groups 
o Aminopenicillin examples are amoxicillin and ampicillin 
 Cephalosporins – first, second, third, fourth generations and cephamycins 
o Ceftiofur is the third generation cephalosporin labeled for use in food animals 
with injectable and intramammary approvals 
o Cephapirin is the first generation cephalosporin approved for intramammary use 
in dairy cattle. 
94 
o Cephalosporins are prohibited from any use in food animals which does not 
conform to the label regimens, meaning that use in water is prohibited since there 
are no labels including use in water. 
 Carbapenems – another beta-lactam group (related to penicillins and cephalosporins) with 
no veterinary labels 
 Monobactams - another beta-lactam group (related to penicillins and cephalosporins) 
with no veterinary labels 
 Quinolones – the forerunner group to the fluoroquinolones, there are no veterinary labels 
from this group 
 Fluoroquinolones – Enrofloxacin was once labeled for water use in poultry but this label 
was removed by the FDA/CVM in 2005. The sarafloxacin label for water use in poultry 
was withdrawn by the sponsor in 2000. 
o Enrofloxacin is labeled for injectable treatment and control of respiratory disease 
in cattle (including dairy heifers less than 20 months of age) and in swine. 
o Danofloxacin is labeled for injectable treatment of respiratory disease in beef 
cattle. 
o Extralabel use of the fluoroquinolones is prohibited in food animals. 
 Glycopeptides – no veterinary labels and prohibited for extralabel use in food animals 
 Oxazolidones – no veterinary labels 
 Pyrazinamide – no veterinary labels 
 Isoniazid – no veterinary labels 
 Rifamycins – no veterinary labels 
 Chloramphenicol  –  no  food  animal  labels  and  prohibited  for  extralabel  use  in  food 
animals 
 Metronidazole – no veterinary labels and prohibited for extralabel use in food animals 
 Polymyxin B – veterinary labels are ophthalmic preparations 
 
A list of affected products, sponsors, and withdrawn products is available on the FDA/CVM 
website.1 There are 283 affected products, including new animal drug applications (“pioneer”), 
abbreviated new animal drug applications (“generic”), and combination new animal drug 
applications (which can be either pioneer or generic). 
 
Guidance 213 – December, 2013 
 
This guidance document puts forth nonbinding recommendations for companies to comply with 
Guidance 209. There was a 3 month period for companies to communicate with the FDA/CVM 
regarding their intent to comply with the voluntary recommendations in Guidance 209. After 
this 3 month period, a 3 year period began for companies to comply. After this period, the 
FDA/CVM would likely take steps to accomplish these goals through other regulatory routes. 
On March 26, 2014, the FDA/CVM released an update indicating that 25 of the 26 affected 
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sponsors have indicated they will comply with Guidance Documents 209 and 213. 2 This 
participation accounts for 99.6% of the affected products. 
 
A company may remove the label indications for growth promotion and insert label requirements 
for veterinary authorization without being subjected to other requirements such as updating the 
label in other areas (e.g., microbial safety). The guidance document also provides suggested 
pathways for companies who elect to pursue prevention, control, or therapeutic claims for the 
regimen previously labeled as a growth promotion claim. The document also makes it clear that 
generic versions of original proprietary labels must alter their labels to reflect any changes in the 
original label. 
 
Veterinary Feed Directive (VFD) proposed regulation – December, 2013 
 
This proposed regulation has 5 key changes in the existing VFD regulation 
 
 User friendly reorganization of the VFD rule 
 Increased flexibility for licensed veterinarians issuing VFDs 
o The current regulation requires veterinary “supervision” for a VFD to be written. 
The proposed regulation changes this to “supervision or oversight”. 
o The proposed regulation removes the explicit veterinary-client-patient 
relationship (VCPR) provision and replaces it with the requirement that 
veterinarians ordering the use of VFD drugs must be “in compliance with all 
applicable veterinary licensing and practicing requirements”. This defers the 
VCPR standard to the veterinary profession and the individual states to determine 
the requirements of a valid VCPR. 
o The veterinarian will be required to specify duration of use, approximate number 
of animals to be fed the medicated feed, and level of VFD drug in the feed. 
However, they will not be required to specify the amount of medicated feed to be 
dispensed. 
 Continued access to Category I type A medicated feed articles by unlicensed feed mills 
o Currently, a VFD drug is automatically a Category II medicated feed, which 
means that the type A feed article for that drug would only be available to the 
limited number of licensed feed mills.  The proposed regulation would not require 
a VFD drug to automatically become a Category II medicated feed. 
 Increased flexibility for animal producers purchasing VFD feeds 
 Lower recordkeeping burden for all involved parties 
o Duration of record keeping is proposed to be dropped from 2 years to 1 year 
96 
Key Area 2: Regulatory or legislative initiation of antimicrobial use reporting 
 
Current antimicrobial use reporting in the United States consists of aggregate reporting of drug 
classes based on sales figures reported to the FDA/CVM by sponsors as required under the 
Animal Drug User Fee Act (ADUFA) of 2008. The FDA/CVM has recently asked for comment 
on a new form or reporting these sales data, but this proposal does not seem to include more 
detailed information on actual drug use by species, which to my understanding is not possible 
from the reported aggregate sales data which are reported.3 
 
Legislative pressure has been applied in an attempt to bring about more detailed reporting. 
Senator Diane Feinstein put a hold on the Animal Drug User Fee Act (ADUFA) this year in an 
attempt to force inclusion of increased reporting requirements, which was not successful. 
 
Representative Henry Waxman has introduced the “Delivering Antimicrobial Transparency in 
Animals (DART) Act of 2013” as HR 820. As of 3/1/2013 it had been referred to the 
Subcommittee on Health.4 This bill would require increased reporting of antimicrobial sales for 
all food animal antimicrobials, and requires reporting by end users of antimicrobials in the feed. 
 
The FDA/CVM has recently asked for input on how increased antimicrobial use data might be 
collected for food animal uses. This input has been collected and the FDA/CVM is considering 
how additional antimicrobial use information might be collected. I have no idea where this will 
end up, but anticipate some increased reporting burden in the future. 
   
Key Area 3: Will we see legislative prohibition of the use of antimicrobials for prevention 
or control of infectious disease? 
 
Bills which purpose to drive the evaluation of prevention and control uses, but which in fact 
would result in their removal for at least a protracted period of time, continue to be introduced. 
Representative Louise Slaughter has again introduced the latest edition of the PAMTA act, 
“Preservation of Antibiotics for Medical Treatment Act of 2013” (HR 1150).5 This bill has 55 
cosponsors.   This bill does not outright prohibit the use of antimicrobials in food animals for 
anything but individual therapeutic use, but sets a very high bar with a very short timeline to 
retain their use, clearly with the intention of establishing unattainable benchmarks. 
 
On the senate side, Senator Dianne Feinstein has introduced the “Preventing Antibiotic 
Resistance Act of 2013” (S 1256). This bill has 5 cosponsors and is very similar to PAMTA.6 
 
These bills have typically not made it out of committee to the floor, and have been repeatedly 
introduced over the last decade. 
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Key Area 4: Will there be continued confusion by the USDA Food Safety Inspection 
Service in the area of food animal drug testing cutoffs for violative/nonviolative residues? 
 
The USDA Food Safety and Inspection Service has recently initiated a new testing procedure, 
including a multi-residue monitoring (MRM) mass spectrometry test. 7 The FSIS has also 
determined that the tolerances developed for the use class on the label shall not apply to any 
other use class. For example, tolerances developed for Florfenicol in the liver of beef cattle will 
not apply to the liver of a cull dairy cow, and therefore the effective tolerance is the 
“applicability level” of the FSIS testing method (lowest positive result to be called positive). 
 
In this process, FSIS started to issue notices of violative residues to producers supplying 
carcasses in which any residue of dexamethasone was detected. This is because no tolerance for 
dexamethasone is listed in 21 CFR part 556.8 However, the FSIS was made aware by the 
FDA/CVM that no tolerance is listed because the safety of the drug at the time of approval did 
not require that a tolerance be developed. The FSIS announced in a December 6, 2013 
constituent update that they were suspending testing for dexamethasone.9 
 
However, this issue highlights a problematic lack of communication between the FSIS and the 
FDA/CVM at the appropriate scientific level. There is also a need for FSIS to establish improved 
communication with food animal practitioner organizations; the notice that this standard was 
being applied to dexamethasone was in the form of the first violation notices. The FSIS has been 
made aware that publishing in the Federal Resister is not an effective form of communication 
with food animal veterinarians. 
 
Also included in the MRM are both enrofloxacin and the primary metabolite, ciprofloxacin. In 
cattle, the marker residue is ciprofloxacin, which is quantified with the official regulatory test to 
determine if the amount detected is violative. In swine, the marker residue is enrofloxacin, 
although small quantities of ciprofloxacin may be detectable. The FSIS has detected 
ciprofloxacin in pigs and classified that as a violative residue because there is no swine tolerance 
for ciprofloxacin in 21 CFR Part 556, even though the marker residue (enrofloxacin) was below 
the tolerance. This is an inappropriate designation of a new marker residue and will hopefully be 
corrected in the near future; the marker residue being below the tolerance eliminates the need to 
evaluate other residues because they were accounted for during the approval process. This issue 
again indicates that communication between FSIS and the FDA/CVM must be improved, and 
that FSIS needs to seek input on testing cutoffs beyond just presence or absence of a tolerance in 
21 CFR Part 556. 
 
Another issue is that of packing plants placing high pressure on suppliers for non-violative 
residues. In no case should producers be punished for detected but non-violative residues. As an 
industry, we must be very aggressive in pushing back against such actions, and any implied need 
98 
to do so by USDA personnel. There should also not be any pressure applied to extend 
withdrawal times for label use of drugs beyond the label withdrawal times. These withdrawal 
times have been determined to be safe during the approval process, and under no circumstances 
should we tolerate the precedent of extending them for animals being slaughtered for domestic 
consumption. 
   
Key Area 5: Will there be another use of the AMDUCA regulations for regulatory action 
directed towards a drug class for food animal species? 
 
The Cephalosporin  ELDU  prohibition  is  an  example  of  a very troubling  precedent. 10 The 
primary concern is that even though there was absolutely no evidence to separate concerns 
regarding label and extralabel use, the action was taken directed at extralabel use. The use of the 
AMDUCA regulations as a lower-resistance regulatory pathway is troublesome to those who 
invested considerable effort in both the act and the regulation promulgation process, resulting in 
legalizing extralabel use in veterinary medicine. 
 
There is also a concern over species inclusion. Regardless of the lack of evidence to indicate a 
concern for swine, this species is included in the prohibition. In the evidence cited for cattle, the 
authors of two of the papers state in the discussion that you really can’t make the conclusion 
from the paper for which they are used in the FDA decision, which in my opinion was obvious 
from reading the articles. The FDA also left out key articles related to cephalosporin use in 
cattle that were not supportive of their stance on the issue. The key evidence which really 
supported the ELDU ban was for the injection of chicken eggs and the resulting change in 
susceptibility profiles of surviving Salmonella. The evidence for concern in cattle was paltry at 
best, and nonexistent for swine. 
 
The cephalosporin ELDU prohibition is a product of the need for a visible action on 
cephalosporins due to pressure on the FDA/CVM, and the selection of the easiest route to enact 
regulatory action on the drug class. Just to be clear about this prohibition, there are multiple 
misperceptions involved in the document. For example, the Agency implies that the label 
regimen is the best to minimize selection for resistance. In fact, there is absolutely no evidence 
to support this claim. The label regimen is developed based on efficacy, not on suppression of 
resistance selection. We don’t even have evidence to support optimal duration of antimicrobials 
for therapy, let alone the relationship of duration and magnitude of exposure to the potential for 
selection of resistant organisms during therapeutic protocols. 
 
The prohibition allows the use of ceftiofur for extralabel indications but not with an extralabel 
regimen.  The result of having the ability to use an antimicrobial for off-label indications but not 
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the ability to adjust the dosage appropriately is completely nonsensical, and is likely to 
contribute to selection for antimicrobial resistance. 
 
The most telling direct quote from the order of prohibition was from the section refuting the 
allegation that the FDA/CVM was relying on the precautionary principle. “In the preamble to 
the final rule, FDA addressed the question of what type of evidence would be necessary by 
saying that the risk determinations that would lead to prohibition of an extralabel use 
typically will involve documented scientific information. However, the Agency believes that it is 
not limited to making risk determinations based solely on documented scientific information, 
but may use other suitable information as appropriate.” In other words, there is a drastically 
different standard of evidence between what is required of a drug sponsor submitting a new 
animal drug application, and what is required of the FDA CVM. 
 
While the current FDA/CVM leadership is committed to prevention and control uses being 
classified as judicious, therapeutic uses of medically important antimicrobials, future leadership 
may not share this view and the precedent of the evidence standards in the cephalosporin ELDU 
prohibition are troublesome. 
   
Key Area 6: Will the FDA Center for Veterinary Medicine be forced to hold hearings on 
whether the use of penicillins and tetracyclines in animal feed 
is a hazard to human health? 
 
In 2011, The National Resources Defense Council (NRDC), the Center for Science in the Public 
Interest, Food Animal Concerns Trust, and the Union of Concerned Scientists, filed a lawsuit 
against the FDA/CVM in the U.S. District Court for the Southern District of New York.11 This 
lawsuit sought to force the FDA/CVM to act on the 1977 Notice of Opportunity for a Hearing 
(NOOH) which sought to address the use of tetracyclines and penicillins in animal feed. On 
March 22, 2012, the magistrate judge ruled that the U.S. Food and Drug Administration must act 
on the 1977 NOOH regarding in-feed use of tetracyclines and penicillins in animal feeds.12 The 
FDA/CVM had withdrawn this NOOH in December of 2011. The FDA Commissioner 
(Margaret Hamburg), Secretary of Health and Human Services (Kathleen Sebelius), and Director 
of the FDA/CVM (Bernadette Dunham) appealed this decision in the United States Court of 
Appeals, Second Circuit, on May 21, 2012.13 
 
The history leading up to the NOOH and subsequent activities of the FDA/CVM on this issue 
were detailed in a presentation by two FDA/CVM representatives at a the symposium “Public 
Health Implications of the Use of Antibiotics in Animal Agriculture” held as part of the Annual 
Meeting of the American Society of Animal Science in August of 1985. 14 In 1981, the 
FDA/CVM was instructed by the house appropriations committee to hold in abeyance any 
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implementation of the proposed withdrawals pending the results of studies to evaluate the 
relationship of feed use of these antimicrobials to human health. 
 
The NRDC has previously filed a petition with the secretary of Health and Human Services to 
declare the subtherapeutic use of penicillin and the tetracyclines in animal feeds an imminent 
hazard to the public health (Nov 20, 1984). The FDA/CVM held a “legislative type” hearing on 
January 25, 1985 to evaluate the evidence. If the Secretary would have found the use of these 
antimicrobials to be an imminent hazard to public health, a formal evidentiary public hearing 
before an administrative law judge would have been required for removal of these uses. 
 
Obviously, the use of these antimicrobials in feed has not been withdrawn as of the writing of 
these proceedings. However, should the appeal be unsuccessful, then the hearing may be held 
and the drug sponsors and the industry will likely be put in the position of having to defend these 
uses. The definitions of the terms “subtherapeutic” and “nontherapeutic” will be crucial as to 
what uses are considered in the hearing, especially in relation to uses for prevention and control 
of disease. Also in play will be the ability, or perceived ability, of GFI #209 to achieve the goals 
of the original 1977 NOOH. In my opinion, if this hearing occurs, it will be a telling precedent 
for the future of uses of antimicrobials for the prevention and control of diseases in food animals; 
it won’t just be about tetracyclines and penicillins. 
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Introduction 
 
Veterinary medicine and agriculture have historically lacked needlestick injury (NSI) research, 
education, and mitigation due to the relative absence of zoonotic blood-borne pathogens and the 
“perceived” benign nature of the injury. However depending on the procedure/pharmaceutical 
used, these injuries may include mild/severe bacterial or fungal infections, lacerations, local 
inflammation, vaccine/antibiotic reactions, amputation, miscarriage, and death. The objective of 
this report is to identify published case reports and case series/surveys on human needlestick 
exposure to veterinary biologics, and to review literature and educational documents describing 
needlestick prevention strategies for agricultural workers and veterinarians.  
 
Methods 
 
An electronic database search was conducted using PubMed© and CABI©. Key search terms: 
PubMed© - "Needlestick Injuries" [MeSH] veterinar*, "Vaccination/veterinary"[MeSH]) AND 
"Occupational Exposure"[MeSH], "Vaccination/veterinary"[MeSH]) AND "Occupational 
Exposure"[MeSH]; CABI© - needlestick injuries.sh.  Article inclusion criteria were those 
detailing NSI in agricultural workers only. Abstracts of all search results were read and relevant 
articles compiled into a RefWorks© database. References cited within articles were examined to 
locate additional articles.  
 
Results 
 
Fifty-six articles were identified. Literature consisted of case reports (n=14), survey/case series 
articles (n=11), prevention guidance documents (n=6), and background articles (n=25). A total of 
48 cases were found. Twenty-four identified injury location: 13 (54.2%) NSI to the hands: three 
to the right, eight to the left, and two were not specified.  Eight injuries were to the legs (33.3%): 
five to the right and three were not specified. Of the 48 cases, 11 (22.9%) involved oil-
adjuvanted vaccines. The remaining products included: other vaccines, antibiotics, 
analgesics/sedatives, and hormones. Forty-six (95.8%) of 48 cases reported seeking medical 
attention. Of the six survey/case series articles: two focused on oil-adjuvant products, one on 
Brucellosis RB51 vaccine, and three on tilmicosin. General recommendations from guidance 
documents included: proper animal restraint, avoid recapping needles, do not bend needles, do 
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not put needle caps in your mouth, provide appropriate training, provide sharps containers, report 
injuries, seek medical attention.  
 
Conclusion 
 
NSI in agriculture workers and veterinarians can result in injury and loss of work. It appears that 
NSI awareness is limited among workers. There is a need for comprehensive programs to 
prevent NSI on livestock operations.  
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Organic Dairy Farms in Minnesota 
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Organic agriculture has tremendously increased in the previous decade in the United State. The 
number of organically certified dairy cows has increased by 6-fold from approximately 38,196 in 
2000 to 249,766 cows in 2008 (NASS, 2012) and organic dairy herds represent approximately 
3% of dairy herds in most States, including Minnesota. To produce organically, dairy producers 
have to adhere to the regulations of the National Organic Program (NOP) of the USDA-AMS 
(USDA, 2012). Third party certifiers audit the farms to ensure compliance with the NOP. The 
rules require that ruminants over 6 months of age are receiving a minimum of 30% of their dry 
matter through pasture for 120 days/year, are fed and bedded on organically certified feedstuffs 
only and only drugs and their route of administration that are specified in the NOP may be used 
on organic farms. The use of antibiotics, hormones and most paraciticides is principally 
prohibited. The exceptions are Ivermectin, Fenbendazol, Moxidectin if a heavy infestation is 
diagnosed by a veterinarian. Animals that are treated with antibiotics have to leave the dairy and 
cannot be sold as organic anymore. However, if the allowed substances are ineffective in treating 
a sick animal, then organic farmers must not withhold antibiotics or other effective therapies just 
to save the organic status of their animals. Organic advocates claim that organic cows are 
healthier, while opponents of organic agriculture fear that the lack of antibiotics may pose a risk 
for animal welfare, should an animal get seriously sick. Some recently conducted studies have 
found little difference in health events or bulk tank somatic cell counts between organic and 
conventional farms (Sato et al., 2005; Cicconi-Hogan et al., 2013) while others found lower 
reported incidence of clinical mastitis in organic herds (Richert et al., 2013).   
 
Therefore, in 2012, a pilot study was conducted in Minnesota to capture management practices 
and health incidence on organic and conventional herds in Minnesota. All organic herds (n=114) 
were invited to participate. In addition, conventional herds were enrolled in the similar region. At 
the visit, a questionnaire about management practices and health was administered and 
environmental fecal composite samples were taken for detection of Mycobacterium avium subsp. 
paratuberculosis (MAP), a bulk tank sample was collected, fecal grab samples of 20 breeding 
age heifers was collected for parasite egg count (Wisconsin sugar float method) and a 
representative sample or all of the mature cows (if herd < 100 cows) was assessed for lameness 
(score 1-5), body condition (score 1-5), hock (score 1-3) and hygiene (1-4).   
 
In the end 35 organic herds and 38 conventional herds participated. Herds were visited once 
between June and August 2012. Two organic herds were visited later in October and November. 
Furthermore, some of the conventional herds were larger than the organic herds despite best 
efforts to enroll predominately grass based herds of similar size to the organic herds. Therefore, 
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the conventional herds were split into small (<200 mature cows, SC) and large (≥200 mature 
cows, LC) conventional herds. Appropriate statistics were used to compare management 
practices and reported disease incidence and measure parameters among the 3 herd types. 
The median organic herd size was 68 milking cows (interquartile range: 42-110). Organic dairy 
herds tended to have higher proportion of 3+lactation and more cross-bred cows than 
conventional herds, but the average age of the oldest cow did not differ between organic and 
conventional herds. The average milk production was significantly lower and the latest bulk tank 
SCC tended to be higher in organic herds, but the average annual bulk tank SCC, number of 
cows with <4 functioning quarters and the bacterial burden of the collected bulk tank sample 
were comparable among farm types. The proportion of lame cows (~25%) as well as the hygiene 
scores also did not differ between herd types, but organic herds had lower hock lesion scores 
than conventional herds. The SC and organic herds (47% and 43%, respectively) were less likely 
to test positive for MAP than the LC herds (92%). The average number of parasite eggs per gram 
(epg) was overall low and only 4 of over 1,100 heifers had more than 500 epg. However, organic 
herds had, on average, higher fecal egg counts than conventional herds. Most diseases as well as 
the percent of died cows were reported at a slightly lower rate on organic farms than 
conventional farms.  
 
Although there were many similarities, several differences between organic and conventionally 
managed herds were noted in this pilot study and future studies need to investigate further which 
management practices are most useful to ensure animal health on organic dairy farms. 
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